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Abstract
The elderly population is inherently more susceptible to gastrointestinal problems and diseases
due to significant age-related gastrointestinal changes experienced in gut physiology, reactivity
of the immune system, and/or diet. These factors, coupled with increased occurrence of disease
and corresponding medication use, could also modify the composition of gut microbiota. The
impact of non-steroidal anti-inflammatory drugs (NSAIDs) on the physical gastrointestinal tract
has already been shown. However, the impact of these factors on the microbiota inhabiting the
GI tract has not been well established. A better understanding of the relationship between
medication use and gut microbiota composition may have beneficial implications for general and
elderly health. Increasing knowledge on the health benefits of probiotics among consumers has
dramatically surged the use of probiotics in the recent decades. The objective of this study was to
determine the impact of commonly administered medical drugs and commonly consumed
caffeine on the viability and functionality of commercially available probiotic supplements. Ten
probiotic supplements containing various strains of bifidobacteria (B. longum, B. bifidum, B.
lactis, B. breve, B. infantis) and lactobacilli (L. acidophilus, L. rhamnosus, L. reuteri, L. gasseri,
L. plantarum, L. casei, L. brevis, L. salivarius, L. paracasei) were individually grown in
laboratory medium de Man, Rogosa and Sharpe (MRS) broth at 37°C for 24 h. Batches of 10 mL
MRS broth were mixed with 100 µL of aspirin stock, inoculated with 1 mL overnight grown
probiotic culture, and then incubated at 37ºC for 2h. Bacterial populations were determined at 0
and 2h of incubation. In addition, bile resistance, β-galactosidase activity, reducing power, and
protein expression were examined. Our results showed that six out of the ten commercial
probiotic supplements contained bacterial populations as claimed on their respective labels. The
β- galactosidase activity of each supplement was determined. The enzyme activity ranged from 1
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to 1,120 Miller units. A single supplement was selected for continued testing in objective 2.
Exposure to one tablet of aspirin was found to decrease bacterial population approximately 6.75
log CFU/ml, and exposure to caffeine (0.5% w/v) decreased population approximately 0.23 log
CFU/ml. Determination of β- galactosidase activity resulted in reductions in enzyme activity post
aspirin exposure and caffeine enhanced enzyme activity.
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1 CHAPTER 1
Introduction
As the aging process proceeds, the elderly naturally encounter a decrease in the number
of beneficial bacterial species present in the microbiota. The stability of gut microbiota in the
elderly is affected by physiological changes in the gastrointestinal tract stimulated by increasing
age. Combined with factors such as changes in lifestyle and diet, diminished performance of the
immune system could negatively impact the presence of microbes (Biagi et al., 2010). Because
natural declines in physiological function commonly occur with age, this decline may indirectly
alter the composition of gut microflora due to the influence of absorption and/or metabolism of
nutrients. Decreased muscle bulk, coupled with tooth loss, causes mastication, and, in some
cases, swallowing difficulties (Karlsson, Persson, & Carlsson, 1991; Newton, Yemm, Abel, &
Menhinick, 1993). Diminished sensory sharpness leads to increased blandness in food flavor
(Weiffenbach, Baum, & Burghauser, 1982). The combination of these factors can result in
nutritionally imbalanced diets in the elderly population.
The reduction of beneficial bacteria in the gut microbiota of the elderly is often
exacerbated by an increase in the consumption of medications consumed as a result of an
increase in the occurrence of illnesses commonly associated with aging. Common ailments
suffered by the elderly are often treated with a range of medications, from non-steroidal antiinflammatory drugs (NSAID), to acetaminophen (Tylenol). Individuals consuming probiotic
products sparingly and inconsistently are not equip to withstand the potential decline in bacterial
population. Therefore, medication use could alter their microbiota composition, and cause
potential gastrointestinal problems and diseases.
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In recent years, considerable effort has been made to investigate the positive impact of
probiotics on health. Probiotics are live microorganisms administered in adequate amounts that
confer a beneficial health effect on the host. Traditionally probiotics have been consumed via
dairy products such as milk, cheese, and yogurt. The most commonly used probiotics in foods
are Lactobacillus and Bifidobacterium. For centuries, lactic acid bacteria (LAB) have been
utilized in food fermentation, and the functions of these food fermenting agents have expanded
to also include potential as conferrers of health benefits (Song, Ibrahim, & Hayek, 2012). Lactic
acid bacteria are nonpathogenic, and are generally recognized as safe (GRAS). Recent studies
have demonstrated that the effects of probiotics can potentially be further improved (Gyawali &
Ibrahim, 2012). Plants rich in micronutrients such as manganese and zinc have been shown to
enhance the ability of probiotics to produce organic acids. These organic acids offer potential as
a natural antimicrobial, thus improving the safety of foods and supporting human health (S.
Ibrahim, Dharmavaram, Seo, & Shahbazi, 2003; Nakashima, 1997). Enzymes also enhance the
production of organic acids such as lactic and acetic acids, which act as antimicrobial agents and
suppressors of pathogenic bacteria growth (S. Ibrahim et al., 2003; S. A. Ibrahim & Salameh,
2001; Nakashima, 1997).
The promotion of health via probiotic supplements, however, has not been well
established. A broader selection of probiotic supplements to choose from benefits consumers and
has the potential to increase the likelihood of purchase. Currently probiotics are available as
dietary supplements in the form of capsules, tablets, powders, liquids, and chews. The elderly
population benefit from the convenience of multiple probiotic supplements as well because the
assortment of forms allows them to select a product that caters to their mastication or swallowing
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abilities. Elderly with weak swallowing abilities are now able to choose a liquid or powder form
of a probiotic supplement for increased ease of administration.
Despite the negative impact medical drugs have on the microbiota, these medications are
necessary in order to mitigate pain and other health problems experienced by the elderly. This
has prompted scientists to look for alternative means to combat these negative effects and
enhance the beneficial bacteria of the microbiota. In recent years, considerable effort has been
made to identify dietary therapeutics for this purpose. The most practical application for elderly
individuals to combat the negative impact of medications is to maintain a well-balanced daily
diet that also includes probiotics each day. The first objective of this study was to examine the
viability of probiotics in commercial dietary supplements. The second objective was to
determine the impact of aspirin and caffeine on the functionality of a probiotic supplement. In
this project, functionality was determined by performing β- galactosidase activity, bile resistance,
reducing power, and protein expression.
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2 CHAPTER 2
Literature Review
2.1 Aging
2.1.1 The Current Situation
In recent years there has been a dramatic rise in the elderly population as a result of an
increased life expectancy that can be contributed to innovations in science and medicine (E.
Woodmansey, 2007). However, most elderly individuals are not necessarily experiencing
longevity, which is the potential to live a long life in a healthy state (Saunier & Doré, 2002). The
elderly population is inherently more susceptible to gastrointestinal problems and diseases due to
significant age-related gastrointestinal changes experienced in gut physiology, reactivity of the
immune system, and/or diet. Studies have demonstrated the need for an emphasis on gut
microbiota homeostasis as a means of experiencing longevity, given the importance of the
microbiota in elderly health. Factors commonly associated with aging often lead to compromised
microbial balance of the elderly microbiota. When dietary habits cannot support this balance,
alternative methods, such as the consumption of probiotic products is an option for promoting
gut microflora homeostasis.
Aging is a significant topic of concern throughout the world. By definition, aging is the
‗regression of physiological function accompanied by advancement of age‘ (Imahori, 1992). By
2040, the US Census Bureau estimates that the elderly population will double from 7 percent to
14 percent of the total world population; for the first time in history, within the next 10 years,
there will be more people in the world aged 65 and over than children under 5 (Kinsella, 2009).
In the state of North Carolina alone, the number of people age 65 and up has increased 25.7
percent between 2000 and 2010; 12.9 percent of the state‘s total population. According to the
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UNC Institute on Aging, between 2010 and 2030 North Carolina‘s elderly population will
increase by 400,000 people per decade, reaching 2.14 million or about 18 percent of the state‘s
total population by 2030 (Aging, 2011). In 2010the U.S. Bureau of the Census calculated
individuals‘ 65 years and up as a percentage of total population (Fig. 2.1) in the United States.
Increases in the elderly population correlates with increases in financial burdens caused by
healthcare needs, treatment costs, and end of life expenses.

Figure 1 The percentage of elderly individuals in 2010 by state.
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Bacteria colonize all of the physically available space along the gastrointestinal tract,
with varying distribution. These bacteria have invaluable functions in the human body. ―
Human
beings have been recently reviewed as ‗metaorganisms‘ as a result of a close symbiotic
relationship with the intestinal microbiota. This assumption imposes a more holistic view of the
aging process where dynamics of the interaction between environment, intestinal microbiota and
host must be taken into consideration.‖ (Biagi et al., 2010) There are several genetic and
metabolic attributes provided by gut bacteria that humans remain unable to evolve independently
(Bäckhed, Ley, Sonnenburg, Peterson, & Gordon, 2005). The relationship between human host
and the composition of its gut microflora is primarily mutually beneficial. The metabolic activity
of the gut microbiota provides the human host metabolic energy and absorbable substrates and
nutrients, while the human host provides the microbiota a source of energy and nutritious
products for growth and development.
An essential feature of a healthy gut microbiota is the production of short chain fatty
acids (SCFA) such as acetate, butyrate, and propionate(Barcenilla et al., 2000; Louis & Flint,
2009). SCFA have a nutritious effect on the intestinal epithelium. Each of the three major shortchain fatty acids stimulate epithelial cell proliferation and differentiation in the large and small
intestine in vivo (Butler, Sun, Weber, Navarro, & Francis, 2000). The microbiota also ferments
carbohydrates, which provides energy to the colon; serving 50% of the daily energy
requirements, for colonic epithelial cells (Tuohy, Probert, Smejkal, & Gibson, 2003).This energy
production is accomplished by fermenting butyrate, a carbohydrate, into organic acids (Tuohy et
al., 2003). Butyrate is active in the physical separation of the microbiota and enterocytes; as a
result of this separation the release of mucins, the protein component of the mucus layer that
forms gel, is stimulated (Barcelo et al., 2000; Petersson et al., 2011).
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Additional general health benefits conferred to the host by the gut microflora include
immunostimulation, synthesis of vitamins, improved digestion and absorption, cholesterol
reduction, lowered gas distension, and inhibition of potentially pathogenic bacterial growth
(Wallace et al., 2011). Health benefits conferred to the host are contingent upon maintaining a
homeostatic state amongst the network of microflora.
Common declines in health, specifically gut microbiota health, occur with aging. ―
Agerelated physiological changes in the gastrointestinal tract, as well as modification in lifestyle,
nutritional behavior, and functionality of the host immune system, inevitably affect the gut
microbial ecosystem.‖ (Biagi et al., 2010) Increased occurrence of disease and corresponding
medication use in the elderly also modify the composition of the gut microbiota (Tiihonen,
Ouwehand, & Rautonen, 2010). Members of the elderly community encounter unfavorable
changes in microbiota, which can lead to health problems.
The microorganisms of the gastrointestinal tract are not indestructible, and the positive
attributes provided by the bacteria can be overcome by pathogens. Some pathogens have evolved
specifically for gastrointestinal infection, examples include Salmonella spp., Escherichia coli
strains and Campylobacter jejuni (Tuohy et al., 2003). The balance can be delicate, and many
age related physiological issues potentially lead to harmful effects caused by the gut microflora;
examples include intestinal putrefaction, carcinogen production, liver damage, production of
toxins, diarrhea and/or constipation, and intestinal infections (Wallace et al., 2011).
2.1.2 Development of gut microflora
The human intestinal tract is home to over 14 log microorganisms; 10 times greater than
the total number of somatic and germ cells found in the human body (Bäckhed et al., 2005).
―
Our gut microbiota can be pictured as a microbial organ placed within a host organ: It is
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composed of different cell lineages with a capacity to communicate with one another as well as
the host; it consumes, stores, and redistributes energy; it mediates physiologically important
chemical transformations; and it can maintain and repair itself through self-replication.‖
(Bäckhed et al., 2005)
At birth the gastrointestinal tract is a sterile environment (Wallace et al., 2011). This
assemblage of bacteria begins colonizing immediately after birth. Factors such as vaginal versus
caesarean birth, as well as breast versus formula feeding are among the first to impact gut
flora(Guarner & Malagelada, 2003). The only significant changes in the gut microbiota occur
during infancy, after which a relatively stable environment is maintained throughout childhood
and adult life (Favier, Vaughan, De Vos, & Akkermans, 2002; Zoetendal, Akkermans, & De
Vos, 1998). The initial colonization heavily influences the final composition of the permanent
flora in adults (Guarner & Malagelada, 2003).
Healthy individuals typically have an intestinal habitat of 300 to 500 different species of
bacteria (Guarner & Malagelada, 2003). Bacteria colonize all of the physically available space
along the gastrointestinal tract, with varying distribution. Each species occupies a niche in a
particular habitat. The gastrointestinal tract is deceptively long. It has been calculated to be 150200 m2 (Waldeck, 1990). Surface area of the gastrointestinal tract, specifically the small intestine
is increased via folding, ‗e.g.: three-fold by forming circular folds, 7-10 fold by folding of the
epithelium (intestinal villi) and 15-40 fold by the formation of microvilli in the enterocyte
resorptive luminal membrane.‘ (Holzapfel, Haberer, Snel, & Schillinger, 1998). The gut
microflora increases in quantity and diversity as one moves along the gastrointestinal tract. In the
stomach, the bacterial count is about 101cells/gram, and includes Lactobacillus, Veillonella, and
Helicobacter. The duodenum, jejunum and ileum of the small intestine possess bacterial counts
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of 103, 104, 107cells/gram respectively which include Bacilli, Streptococcaceae, Actinobacteria,
Actinomycinaeae, and Corynebacteriaceae. Lastly, the colon houses a bacterial count of
1012cells/gram consisting of Lachnospiraceae and Bacteroidetes.

Figure 2 Gut microbiota. a) The numerical breakdown of gut microorganisms along the GI tract.
b) The bacterial composition of the intestinal wall. c) The evolution of bacteria during aging.

Current sample collection methods used to analyze diversity of the microbiota are limited
by the difficulty of access. Fecal samples are commonly used due to the convenience of
collection. However, bacteria from these samples do not fully represent the total population of
the gut microbiota. Investigators have begun utilizing methods such as molecular finger printing
and 16S ribosomal DNA (rDNA) to explore this ecosystem. Various studies have shed light upon
the composition as it has been accessed. The gut microbiota is predominately strict anaerobes,
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but facultative anaerobes and aerobes are also present. To date, over 50 bacterial phyla have been
identified in the human gut, but two remain in the forefront of importance Bacteroides and
Firmicutes; occurring in lower magnitude are Proteobacteria, Verrucomicobia, Actinobacteria,
Fusobacteria, and Cyanobacteria (Eckburg et al., 2005; Schloss & Handelsman, 2004).
Each phyla, species, and strain of bacteria has an individual role that often time only they
specifically are able to perform. Certain bacteria are able to metabolize a wide variety of
substrates, while others have more specialized abilities.
About 30% of the gut microflora is composed of Bacteroides of the phylum
Bacteroidetes (Salyers, 1984). Notable species to mention include B. thetaiotaomicron,
B.vulgatus, B. distasonis and B. fragilis (Salyers, 1984). The Bacteroides species are recognized
as starch degraders. Additional strains have been found to degrade certain types of structural
polysaccharides as well. The high population of Bacteroides in the gut is believed to be caused
by the import of oligosaccharides for continued hydrolysis.
2.1.3 Changes in the composition of gut microflora
The adult gut microbiota is primarily composed of non-sporing anaerobes, the most
prominent being Bacteroides spp., Eubacterium spp., Clostridium spp., Lactobacillus spp.,
Fusobacterium spp., as well as a variety of other gram-positive cocci (Wallace et al., 2011).
Present in fewer numbers are Enterobacteriaceae, methanogens and dissimilatorysulphatereducing bacteria (Wallace et al., 2011). The anaerobic environment, characteristic of the
gastrointestinal tract, is produced by the metabolism of oxygen by the microbiota (Wallace et al.,
2011). The composition of the gut is individualized, and varies based on one‘s history and
encounters with conditions such as acute diarrheal illness, diet, and antibiotic treatment (Guarner
& Malagelada, 2003).
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The organization of the symbionts remain relatively stable during adult life, however agerelated changes, such as changes in diet, environment and host immune system reactivity,
influence the microbiota population composition (Hooper & Gordon, 2001; E. Woodmansey,
2007). The changes that occur in microfloral bacterial populations can be seen in Figure 3.
―
Recent studies indicate shifts in the composition of the intestinal microbiota, potentially leading
to detrimental effects for the elderly host. Increased numbers of facultative anaerobes, in
conjunction with a decrease in beneficial organisms such as the anaerobic lactobacilli and
Bifidobacteria, amongst other anaerobes, have been reported.‖ (E. Woodmansey, 2007).
Additional studies have also concluded that with increasing age the number of viable
Bacteroides decreases (Hopkins & Macfarlane, 2002; E. J. Woodmansey, McMurdo,
Macfarlane, & Macfarlane, 2004). This is notable due to the nutritional versatility of the
Bacteroides species. Bacteroides are capable of using a broad assortment of carbon sources and
are believed to conduct the majority of the polysaccharide digestion in the colon (Salyers, 1984).
The normal microbial balance of the elderly gut is very delicate therefore malfunctions in
gastric function, or intestinal motility have a major impact on health. ―
Changes at species level
of such a nutritionally important sub-population could have considerable consequences for the
elderly host, because of alteration in metabolic activities, and for other bacteria in the ecosystem
that rely on a complex cross-feeding network within the gut.‖ (Gibson, Cummings, &
Macfarlane, 1988) Reports of the changing microbiota of the elderly include increased numbers
of lactobacilli, clostridia, and facultative anaerobes (T Mitsuoka, Hayakawa, & Kimura, 1974;
Tomotari Mitsuoka, 1990). Decreases in bacteria such as F. prausnitzii, E. allii and other
bacteria belonging to the E. rectal/ Roseburia group have been correlated with functional
declines in the elderly microbiota production of butyrate (Biagi et al., 2010). These butyrate
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producing bacteria also have anti-inflammatory properties, and population declines of these
bacteria might support the inflamm-aging process in the gastrointestinal tract of elderly people.
Loss in butyrate production may also play a role in the development of degenerative diseases and
anorexia (Donini, Savina, & Cannella, 2010; Guigoz, Doré, & Schiffrin, 2008).
Essentially, the stability of the gut microbiota of the elderly is affected by the
physiological changes of the gastrointestinal tract stimulated by increasing age; coupled with
factors such as changes of lifestyle and diet, and diminished performance of the immune system
(Biagi et al., 2010).

Figure 3 Changes of intestinal microflora with age.

(Tomotari Mitsuoka, 1978)

2.1.4 Physiological changes of the gut with age
Natural declines in physiological function commonly occur with age. This decline may
indirectly alter the composition of the gut microflora due to the influence of absorption and/or
metabolism of nutrients. Decreased muscle bulk coupled with tooth loss causes mastication, and
in some cases, swallowing difficulties (Karlsson et al., 1991; Newton et al., 1993). Diminished
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sensory sharpness leads to foods tasting bland (Weiffenbach et al., 1982). The combination of
which can bring about the nutritionally imbalanced diet of the elderly population.
A major physiological change, reported by the elderly, in the gastrointestinal tract is the
reduction in fecal weight (E. J. Woodmansey et al., 2004). ―
Low fecal weights have been
correlated to slow intestinal transit times and reduced excretion of bacterial matter .‖ (Stephen,
Wiggins, & Cummings, 1987) Furthermore, increased retention time is associated with an
increase in bacterial protein fermentation and consequently, the levels of ammonia and phenols
generated in putrefactive processes in the gut.‖ (Macfarlane, Cummings, Macfarlane, & Gibson,
1989)As a consequence of the decreased intestinal motility constipation occurs (Kleessen,
Sykura, Zunft, & Blaut, 1997). The inability to effectively excrete proper levels of harmful
bacteria unfavorably alters the fermentative processes of the gut (Brocklehurst, 1972; Macfarlane
et al., 1989). Thus affecting the intestinal ecosystem homeostasis (Biagi et al., 2010).
Barrier function is another component of the gut potentially compromised with increasing
age. Evidence of barrier importance has been demonstrated via germ-free animals, whose
susceptibility to infections was lessened by the protection of the intestinal barrier (Wallace et al.,
2011). The function of the barrier is carried out by a network of the physical components of the
intestine; villi height, crypt depth, and thickness of mucus. The size and surface area of villi
determine the amount of nutrients able to be absorbed (Yang et al., 2009). Therefore, larger
surface areas, allow larger amounts of nutrients to be absorbed. Similarly, increases in crypt
depth are consistent with digestive efficacy (Guan, 2000). The role of crypts in the intestines is
believed to be associated with facilitating digestion and absorption. Increased crypt depth means
increased crypt cell number, thus increasing digestive efficacy (Guan, 2000).
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2.1.5 Effect of gut microflora on the immune function
The three components of the GI ecosystem, the microbiota, the intestinal epithelium, and
the mucosal immune system, are all vital to the functional and developmental maturity of the
system (Tiwari, Tiwari, Pandey, & Pandey, 2012). The convergence of the microbiota and
immune system begins at infancy, and aids in the development of the immune system. This
partnership lasts throughout an individual‘s lifetime. This network protects against potentially
harmful antigens and microorganisms the human body may encounter from external exposure.
The gut microbiota and gut mucosal surface coexist in close proximity to one another. The single
cell epithelial layer must differentiate this high microbial presence from a persistent threat of
microbial invasion. Humans have developed a specific gastrointestinal immune system in order
to process this risk; to limit tissue invasion by intestinal microorganisms and to preserve the
symbiotic nature of this interaction (Hooper & Macpherson, 2010). The intestinal microbiota is
monitored by the lymphoid tissue, which maintains control by a ‗constitutive low-grade
physiological inflammation‘. This low grade inflammation is based on a network of positive and
negative biological feedback processes. The organization of the gastrointestinal mucosal immune
system facilitates the distinction between harmful pathogens and symbiotic microorganisms.
Thus, generating a strong effector response towards the former and remaining tolerant to the
latter. (Biagi, Candela, Fairweather-Tait, Franceschi, & Brigidi, 2012).
Live bacteria manage the function of the immune system at systemic and mucosal levels.
The management role of the microbiota entails guiding intestinal immune cells into their proper
arrangement. Intestinal immune cells mediate tolerance-inducing responses and are active in host
defense. The cells congregate at inductive sites such as Peyer‘s patches found in the small
intestine, and lymphoid follicles, and colonic patches found in the large intestine; as well as
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effector sites which include the epithelium of the intestine (Garrett, Gordon, & Glimcher, 2010).
The gut epithelial is constantly communicating with the immune cells via intracellular signaling
pathways (Collier-Hyams & Neish, 2005; Rumbo et al., 2004). Innate immune responses are
activated by intestinal epithelial cells, which release chemokines and cytokines. These signaling
proteins control dendritic cell and macrophage responses (Collier-Hyams & Neish, 2005). The
coordination communication and placement of all the components within the network of the
immune system contribute to the proper development of immune cell responses. These responses
will be able to appropriately remove infectious agents and damaged tissues from the body, and
maintain the state of homeostasis within the gastrointestinal tract.

Figure 4 A detailed view of the intestinal and colon walls.
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The barrier formed by the intestinal epithelium and the gut microbiota is designed to
prevent the invasion or uptake of potentially pathogenic microorganisms, antigens, or other
harmful compounds that enter the gut lumen (Holzapfel et al., 1998). Not only are the bacteria of
the microflora efficient as a physical barrier, but are also efficient at digesting antigens.
Specialized transport mechanisms in the villus epithelium and Peyer‘s patches are used to trigger
specific immune responses to target antigens. This barrier remains stable in healthy individuals,
and the human host is provided with protection as well as normal intestinal and immune
function.
Attachment of Lactobacillus and Bifidobacterium, specifically, onto the natural mucosal
barrier prevents the attachment of potentially pathogenic microorganisms (Garcia-Lafuente,
Antolin, Guarner, Crespo, & Malagelada, 2001). The gut microflora not only provides protection
physically, using competitive exclusion by occupying attachment sites, but also by consuming
the nutrients that pathogens would potentially use. This assemblage of microorganisms also
produces antimicrobial compounds (Sekirov et al., 2010).
2.1.5.1 Functional reduction of the immune system with advancing age
Due to the term elderly being used in reference to a population with varying health status‘
it becomes difficult to accurately define an age at which the gastrointestinal environment begins
to experience age-related decline (Biagi et al., 2012).
Immunosenscence is the process in which the functionality of the gastrointestinal
immune system declines (Ostan et al., 2008; Shanley, Aw, Manley, & Palmer, 2009).
Inflammageing is another health decline experienced by elderly individuals characterized by a
chronic low-grad inflammatory status (Franceschi, 2007; Franceschi et al., 2007; Larbi et al.,
2008). The inflammageing process occurs at a localized area of the intestinal mucosa.
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Continuous inflammation is believed to contribute to the systemic inflammation, which may
affect or be affected by the gut microbiota. It is believed that the inflammatory process could be
caused and/or cultivated by an immune response activated unusually by the gut microbiota; this
could be due to decreased mucosal tolerance or age related microbiota composition changes, or
possibly both (Guigoz et al., 2008). Moreover, deficiencies in nutrition, age-related tissue
weakness, and injuries may also contribute to the onset of a pathogenic inflammatory response to
the presence of normally harmless symbiotic bacteria (Schiffrin, Morley, Donnet-Hughes, &
Guigoz, 2010).
2.1.6 Common factors of aging that can possibly affect gut microflora
A variety of factors, or in some cases a combination of factors, onset by old age are
believed to contribute to alterations in gut microflora composition as well as increased incident
of illness/disease experienced by the elderly. Deterioration in dentition, salivary function, and
digestion; changes in living arrangement, and/or socioeconomic status; decreased mobility and
prevalence of disease may all affect the intestinal microbiota upon aging.
Deterioration in dentition is often caused by the lost or reduction in the strength of the
muscles necessary for mastication as well as tooth lose (Karlsson et al., 1991; Newton et al.,
1993). When older people experience weakness in chewing and swallowing their food it leads to
a high likelihood of diet modification to conform to their mastication abilities. However, for
muscle function the diet must include adequate amounts of protein, vitamins and minerals.
Studies observing frailty in the elderly found a relationship between diet and physical
strength, and correlated dietary magnesium with muscle capacity (Fiatarone et al., 1990). Food
sources highest in dietary magnesium include dark leafy greens, nuts and seeds, fish (mackerel),
soy beans, whole grains, bananas and dried fruits. It was also found that subjects with the
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weakest muscle strength had the lowest levels of circulating vitamin D. Food sources highest in
dietary vitamin D include fatty fish such as salmon, tuna, and mackerel; beef liver, eggs, and
fortified fruit juices. For elderly persons with preexisting mastication issues many of these food
products become difficult to break down. Therefore some of the very food products that would
provide the key nutrients needed for maintaining muscle strength are not consumable. As a result
of this problem occurring with a variety of hard to eat foods, the diet becomes nutritionally
imbalanced. This is important because the microorganisms of the gut use the nutrients consumed
for fuel for the host as well as themselves. A nutritionally imbalanced diet leads to both host and
microflora lacking vital nutrients. Ervin, 2008 found elderly individuals who had suffered tooth
lose and rated their health as fair or poor generally consumed fewer servings of fruits and
vegetables, ate a less varied diet and had a poorer quality diet than people with teeth(Ervin,
2008).
Changes in living arrangements and/or socioeconomic status after which elderly persons
move to assisted living facilities are another major contributing factor. In 2009 Dean et al.
reported that factors including appetite, knowledge of food, perceived distance to grocery stores,
access to kitchen amenities or quality food items, and support from family and friends all
contribute to the variety in the diet and nutritional balance of many elderly persons. Depending
on the family circumstances some older individuals live alone, in day hospitals, or in long term
assisted living facilities. Claesson et al. completed a study investigating the microbiota of elderly
individuals of diverse living environments. Individuals residing in long term assisted- living
facilities were found to have less diverse microbiota than those living independently. Results
from this study also indicated that healthy diverse diets promote a more diverse gut microbiota.
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Lastly and most commonly, elderly persons typically experience amplified frequency of
disease. The difficulty of disease in this population is exacerbated by co-morbidity.
2.1.6.1 Diet of the elderly
The influence of diet on the gut microflora is seen as early as birth. As previously
mentioned, the microflora of newborns differs depending on the consumption of breast milk or
formula. Breast fed babies develop a simple microflora composed primarily of bifidobacteria.
Formula fed babies have large numbers of bifidobacteria in addition to species such as
bacteroides and clostridia (Hopkins, Sharp, & Macfarlane, 2002). The impact of one‘s diet
continues into adulthood. The proportion of the macronutrients carbohydrates, protein and fat, in
the diet directly influences the composition of the microbiota.
Diet is the most controllable of all factors encountered by the elderly. Animal and small
scale human studies have shown diet to influence microbiota composition over long periods of
time (Hildebrandt et al., 2009; Mai, McCrary, Sinha, & Glei, 2009; Muegge et al., 2011).
Incorporating a healthy diet is often the first strategy to preserve health among the elderly (Biagi
et al., 2012). The diet provides nutrition and alters the environment for microbes in the
gastrointestinal tract (Lee, 2013). A healthy diet can also impact gut transit time and
pH.―
Scientific and clinical evidence available to date indicates that diet is a major driving factor
for the establishment of the gut microbiome. Slow digestible carbohydrates (human milk glycan,
inulin and fructooligosaccharide), insoluble complex carbohydrates and protein diets favor the
growth of Bacteroides, Clostridium, and Bifidobacterium. Fat on the other hand suppresses the
number of Bacteroides, Clostridium, and Bifidobacterium; whereas polyphenols in general
suppress Bacteroides, Clostridium, but enhance Bifidobacterium.‖ (Lee, 2013)
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Living arrangements must be taken into account when discussing the diet of the elderly.
For those living in nursing homes or other assisted living facilities the composition of diet vary
from elderly persons living independently at home or in the home of a relative. The healthiest of
the elderly population have been found to be those living in a community setting, eating a
balanced and variety diet leads to a distinct microbiota from those in long-term residential care
(Claesson et al., 2012).
2.1.6.2 Medical Drug Use of the elderly
In 2004 Gurwitz completed a comprehensive national survey of the non-institutionalized
adults in the United States and found that more than 90 percent of individuals 65 or older were
using at least one medication per week. More than 40 percent use 5 or more different
medications per week, and 12 percent use 10 or more different medications per week (NHTSA),
2008). Of all the administered prescription drugs, the elderly receive 30 percent of these
medications (Genser, 2008).
2.1.6.2.1 Health benefits of medical drugs
The positive attributes of medical drugs are evident by the extended lives elderly persons
with diseases are able to live. These compounds successfully treat or alleviate ailments that at
one time were considered fatal. Medication therapies are often used as primary and/or secondary
defenses in disease prevention. Primary prevention occurs before the individual acquires a
disease. The objective of primary prevention is to keep individuals from contracting the disease.
This is accomplished via lifestyle modification and/or reducing exposure to disease causing
agents. These primary prevention procedures typically reduce incidence and prevalence of
disease. Secondary prevention occurs after disease has arisen, and serves to control disease
progression. In these instances the disease is found early and is often treatable if not curable.
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Aspirin, or acetylsalicylic acid, has a proven benefit for the secondary prevention of
cardiovascular disease. An estimated 50 million people take aspirin daily as a means of treating
or preventing cardiovascular disease (Chan & Graham, 2004).
3 2.2 Medical drugs commonly taken by the elderly
Common ailments suffered by the elderly are often treated with a range of medications,
from non-steroidal anti-inflammatory drugs (NSAID), to acetaminophen (Tylenol). Medications
are easily accessed over the counter, increasing the likelihood of purchase and self medicating.
Non-steroidal anti-inflammatory drugs or NSAIDs are one of the most widely prescribed
medications in the world, and provide analgesic, antipyretic and anti-inflammatory effects. This
group of medications can be acquired by prescription or over the counter. The types of NSAIDs
available over the counter (OTC) include aspirin such as Bayer ©, Bufferin ©, or Excedrin©;
ibuprofen such as Advil© or Motrin IB©; or naproxen such as Aleve. These are also the
prominent members NSAIDs.
Many are commonly used to treat musculoskeletal and arthritic diseases, at higher
prescription doses, by reducing joint inflammation. At a lower dose NSAIDs also treat a wide
array of pain related issues such as headaches, muscle aches, trauma, dental extraction, and
surgery. Of the three types of non-steroidal anti-inflammatory drugs, all block prostaglandins.
Prostagladins are hormone like substances that triggers pain, inflammation, muscle cramps and
fever.
The active ingredient, acetylsalicylic acid, used in the first non-steroidal antiinflammatory drug, was synthesized by Felix Hoffman in 1897. Aspirin is not only commonly
prescribed to elderly patients in its pure form, but it is also found as an ingredient in many other
drugs.
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2.2.1 Adverse effects of medical drugs on the gut microflora of the elderly
The homeostasis of the intestinal microflora must be maintained in order for good health
to prevail. Advancing age is commonly associated with rising prevalence of disease, the
corresponding medication use for treatment can alter the composition of the gut microflora
(Tiihonen et al., 2010). ―
Elderly patients are the recipients of more than 30% of all prescription
drugs, often given as multiple treatments, so are at higher risk of compromised nutritional status
because of drug-nutrient interactions, for example, loss of body electrolytes.‖ (Genser, 2008) The
elderly are twice as likely to experience an adverse reaction to medical drugs as their younger
counter parts.
There are many reported adverse effects associated with the drugs commonly prescribed
to elderly patients. NSAID drugs are linked to gastric and duodenal damage (Bjarnason &
Takeuchi, 2009; Laine, 1996; Soll, Weinstein, Kurata, & McCarthy, 1991) and opioids to
constipation (Pappagallo, 2001). The more common locations effected by adverse reaction of
drugs are the small and large intestine, which represent 20 to 40 percent of drug side effects
(Zeino, Sisson, & Bjarnason, 2010). ―
The high incidence of small and large intestinal side effects
of drugs is due to the fact that both organs are controlled by a highly delicate interaction between
the autonomic sympathetic and parasympathetic nervous system, the high metabolic activity of
cells involved in absorption and secretion and the intestine is exposed to the greatest
concentration of microbes and is exposed to high drug concentration. The potential for a drug to
adverse affect these pathways is therefore substantial.‖ (Zeino et al., 2010)
Extensive use of NSAID medications is known to affect intestinal health. Damage to the
mucosa of the gastrointestinal tract is the most common adverse effect of non-steroidal antiinflammatory drugs (Bjarnason, Hayllar, MacPherson, & Russell, 1993). Other side effects
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include gastric pain, heartburn, nauseas, vomiting, bleeding, perforation, ulceration, dyspepsia,
and in severe instances hemorrhage and death (Rampton, 1987). It has been shown that 60% of
patients regularly taking NSAIDs have developed intestinal inflammation associated with protein
and blood loss; even upon discontinuing use of the medication patients continued to experience
intestinal inflammation for up to 16 months (Bjarnason et al., 1987).
One study found that NSAID users have a three time greater risk to develop serious
adverse gastrointestinal effects than those that do not use NSAID medication. Researchers also
found that additional risk factors for these potential hazards include being age 60 years or above,
having a previous history of gastrointestinal problems, or are simultaneously using
corticosteroids (Gabriel, Jaakkimainen, & Bombardier, 1991). More than 7000 hospitalizations
and 7000 deaths annually in the United States can be attributed to NSAID induced
gastrointestinal pathology (Davies & Wallace, 1997).
A very common NSAID drug is aspirin. Endoscopic evidence for the damage aspirin can
cause the gastrointestinal tract was found as early as the 1930s by Douthwaite and Lintott. Later
in the 1970s investigators proved that aspirin inhibited prostaglandin production, which is
involved in inflammation. The standard dosage of aspirin is estimated at 325 mg/day. This
dosage has been linked to higher risks of gastrointestinal bleeding, including fatal bleeding, in
comparison to the lower dose of 75 mg (Campbell, Smyth, Montalescot, & Steinhubl, 2007).
Even when administered at low doses aspirin has been found to cause peptic ulceration, ulcer
bleeding, anemia, and the need for transfusion(Roderick, Wilkes, & Meade, 1993; Slattery,
Warlow, Shorrock, & Langman, 1995). Individuals are continually directed to take high doses of
aspirin, despite studies which have shown that higher doses confer no greater benefit in
thrombotic event prevention than the lower doses (Reilly & FitzGerald, 1987).
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2.3 Probiotics
In the early 20th century Eli Metchnikoff made the first observation of the positive role
microorganisms play in human health. Upon studying rural populations in Europe, such as
Bulgaria and the Russian Stepps, Metchnikoff discovered these populations living long lives by
means of diets consisting largely of milk fermented by lactic acid bacteria (Ogueke, 2010).
Officially named ―
probiotics‖ in 1953, these microorganisms were a group of bacterial strains
found to positively enhance the function of the digestive tract (Tiwari, 2012). Later in 2002 the
Food and Agriculture Organization (FAO) of the United Nations defined probiotics as ―
Live
microorganisms administered in adequate amounts that confer a beneficial health effect on the
host.‖
The term probiotic is not synonymous with the naturally occurring beneficial bacteria of
the gastrointestinal tract, although species may be isolated from this source (Douglas & Sanders,
2008). There are guidelines published by the FAO defining probiotics at the strain level (Nations,
2006). Identification of the probiotic strain must properly include the genus and species level in
accordance with current scientific practice, and be named in accordance with current
nomenclature. With the guidelines in place the term probiotic cannot be used as a ―
catch all‖ to
describe undefined combinations of microorganisms (Surawicz, 2004). Once defined, probiotic
strains should be submitted into an international culture collection (Euzéby, 2008). This allows
members of the scientific community the opportunity to replicate published studies.
It is important to take note of the difference between a live, active culture and a probiotic.
Live, active cultures are commonly found in fermented foods, especially fermented dairy
products, but also vegetable products such as sauerkraut. Products containing live active cultures
are not tested for their ability to confer health benefits, as is required of probiotics. Live active
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culture containing products are only tested for their fermentation properties. Therefore, unless
live cultures contribute documented health benefits, they should not be called probiotic (Sanders,
2009).
Probiotic bacteria have an array of biological effects, which include, enhanced: antibody
production, natural killer cell activity, epithelial barrier function, tight junction protein
phosphorylation, and epithelial cell glycosylation; modulation of: host immune response,
dendritic cell phenotype and function, and apoptosis; altered cytokine release; induction of:
regulatory T cells and PPAR-g; inhibition of: proteasome activity and pathogenic bacterial
invasion; and blockade of bacterial adhesion to epithelial cells (Tiwari, 2012). The previously
mentioned barrier created by the gastrointestinal tract and the gut-associated immune system are
vital components of human health. The gut microbiota is an active element in this mucosal
barrier (Kalliomäki, Salminen, & Isolauri, 2008).
2.3.1 Functionality (Viability) of Probiotics
In order for bacteria to be considered for use as a probiotic there are specific functional
characteristics it must possess. Probiotic bacteria should be first and foremost nonpathogenic and
nontoxic. There must be a beneficial effect exerted on the host as a result of the bacteria. It is
essential the bacteria be able to survive the harsh environment of the gut and metabolize there.
By remaining alive in large numbers when reaching the intestines, bacteria should be able to
maintain the balance of the microflora; promoting the growth of friendly bacteria and inhibiting
harmful ones, which is ideal (Tiwari et al., 2012). A good sensory quality is another sought out
virtue if the bacteria it is to be incorporated into a food.
In order for the claimed health effects of the probiotic bacteria to be sustained, the
microorganisms must remain viable during the processing and storage stages (Song et al., 2012).
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This refers to an effective number of viable cells available once the product reaches consumers.
Labeling is also important; probiotic labeling must provide truthful and adequate information to
consumers (Sanders, Gibson, Gill, & Guarner, 2007).
In preparing microorganisms for probiotic use, manufacturers must also take precautions.
When infusing foods with probiotic bacteria, specifically lactic acid bacteria (LAB), the
organisms are present as active microorganisms. This limits the shelf life of the food product to
about a month. ―St
rains should be adapted to a suitable carrier or fermentable substrate (e.g.
milk), and the final product should have an acceptable shelf-life and sensory attributes such as
color, taste, aroma, and texture.‖ (Holzapfel et al., 1998). The bacterial strains present in the
product should remain viable in large numbers and maintain their metabolic activity even after
the expiration date. Dietary supplements, contain the microorganisms in a dormant desiccated
state, which increases shelf life to up to 24 months given that the water activity is kept low
(<0.20) (Ouwehand, Salminen, & Isolauri, 2002). Water activity, in addition to temperature and
pH are major factors in producing probiotic food products and other supplements.
Identifying bacteria worthy of probiotic use is a rigorous process, scientists must test all
bacteria that are to be considered, because probiotic effects are often strain specific, the benefits
associated with one species or strain is not necessarily true for others (Williams, 2010). This
applies even within the same species. It is also important to note that any bacterial strain to be
used for human consumption be tested and approved especially if the strain comes from a non
human source.
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2.3.1.1 Safety of Probiotics
2.3.1.1.1 Consumers
Consumers should not take probiotic consumption lightly. It is important to recognize
the dynamics of bacterial strains present in the product as well as the specific health promotion
the product confers. Variances in genera, species, and strains of bacteria from product to product,
lead to differences in the intent of the product. Claims of efficacy labeled on probiotic
supplements, or products in general, should be target specific, and only made upon successful
testing (Sanders, 2009).
Although foods can never be guaranteed 100% safe, the level of harm to the general
population of healthy individuals consuming probiotics must be low. For probiotic drugs,
however, safety also includes a balance of side effects and potential benefits. Due to the
distinction in standards of safety between probiotic foods and drugs, susceptibility of the target
population determines the proper terminology. The use of the term probiotic drug is advised by
Sanders 2009, to be reserved for a probiotic being administered to an unhealthy population to
cure, treat, or prevent disease. Although considered safe, probiotics could potentially cause side
effects in vulnerable individuals such as systemic infections, harmful metabolic activities,
excessive immune stimulation, and gene transfer(Philippe Marteau, 2001; Philippe Marteau &
Seksik, 2004).
The most commonly used bacteria in probiotics; Lactobacillus, Bifidobacterium,
Saccharomyces, and S. thermophilus all have excellent safety records. These species of probiotic
bacteria hold status as GRAS (generally recognized as safe). This safety covers all age groups as
well as vulnerable individuals with compromised immune systems (Del Piano et al., 2006).
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2.3.1.1.2 Manufacturing
Manufactures must follow a strict process for probiotics prior to products reaching the
market. Figure 5 demonstrates the flow of this process beginning with the identification of
strains. Probiotic strains are identified by genus, species, and strain using phenotypic and
genotypic methods. Once recognized, strains are input into the international culture collection.
Strains are then evaluated for safety and characterized for function. Potential pathogenicity is
tested beginning with the historical epidemiology of the strain. Assessment of probiotic strains
also includes the potential to cause inadvertent disease by way of toxicity, accidental systemic
exposure, and/or administration to vulnerable individuals (Sutton, 2008). The safety evaluation
and characterization of function are conducted via in vitro and animal studies. Upon successful
completion of these tests strains then move on to human studies. Human studies are conducted
using randomized, placebo-controlled, double blind designs. Tests are repeated in order to
confirm results, and ensure the effectiveness of probiotics compared to customary treatment.
Probiotic foods are then manufactured. Labels for these products must include ingredients
(genus, species, strain), minimum number of viable bacteria at the end of the product shelf life,
storage conditions, and company contact information.
According to the Dietary Supplement Health and Education Act (DSHEA) manufacturers
are responsible for ensuring that dietary supplements manufactured or distributed are safe.
Moreover any claims made regarding the supplements must be backed by substantial evidence to
prove they are not false or misleading (Venugopalan, Shriner, & Wong-Beringer, 2010).
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Figure 5 Preparations taken for labeling probiotic supplements.
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2.3.2 Health benefits of probiotics
In recent years there has been a dramatic rise in the interest of probiotics due to
significant benefits imparted on human health. Scientific evidence supporting the health claims
of probiotics stem from in vivo and in vitro studies. Legitimate research groups conduct these
studies and publish the findings in peer-reviewed journals (Gorbach, 2002; Vasiljevic & Shah,
2008). Specific health benefits are contributed by specific strains. Table 1 provides a list of
probiotic stains and their associated health benefit.

Table 1
Health benefits and associated probiotic strains.
Probiotic Strains and associated health benefits
Health Benefit
Immune system stimulation

Probiotic Strain(s)
L. acidophilus, L. casei, L. planetarum, L.
delbruekii

Anti-tumor activity
Protection against acute diarrhea

L. acidophilus, L. casei, L. planetarum, L.
delbruekii, L. bulgaricus, L. helveticus
L. bulgaricus, L. acidophilus, L. bifidus, L. casei

Lactose tolerance improvement

L. bulgaricus, L. bifidus, L. acidophilus, L.
sporogenes

Lowered blood cholesterol levels

L. acidophilus, L. sporogenes, L. bifidus

Improved nutrient absorption and toxin elimination

L. planetarum

Protection against antibiotic associated diarrhea

L. acidophilus, L. bulgaricus

Improves Inflammatory Bowel Syndrome (IBS)

L. sporogenes

Protects against vaginal yeast infections

L. fermenti, L. acidophilus, L. bifidus
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Some of the most important functional effects, backed up by scientific evidence, have
been summarized by Salminen et al. (1996), and include aspects such as immune modulation and
strengthening the gut mucosal barrier, due to: (1) gut microflora modification, (2) adherence to
the intestinal mucosa with capacity to prevent pathogen adherence or pathogen activation, (3)
modification of dietary proteins by the intestinal microflora, (4) modification of bacterial enzyme
capacity especially of those suggested to be related to tumor induction, and (5) influence on gut
mucosal permeability.‖(Holzapfel et al., 1998) While many of these benefits are established and
well documented, some show great potential in animal models, and need claims validated by
human studies (Vasiljevic & Shah, 2008).
One way in which probiotic bacteria are believed to improve human health is by altering
the composition of the normal intestinal microflora. By displacing potentially harmful bacteria
such as clostridia and coliforms, and replacing them with good bacteria such as lactobacilli
and/or bifidobacteria host health is positively impacted (Ouwehand et al., 2002). In the same
scenario, increasing the number of good bacteria is also beneficial to host health. Competition for
attachment sites in the gastrointestinal tract is another benefit probiotic bacteria provide human
hosts. Many strains of bacteria have been found to inhibit adhesion and displace pathogenic
bacteria such as Salmonella, Escherichia coli, Listeria monocytogens, Staphylococcus aureus,
and Clostridium difficile (Collado, Meriluoto, & Salminen, 2007). Investigation of other
probiotic bacteria has led to findings supporting reduction of atopic eczema, vaginal infections,
immune enhancement, rheumatoid arthritis, and liver cirrhosis (Gueimonde, Kalliomäki, Isolauri,
& Salminen, 2006; E. Isolauri, Sütas, Kankaanpää, Arvilommi, & Salminen, 2001).
A specific health issue in which probiotics have been found advantageous is lactose
intolerance. As infants all humans are born with the enzyme lactase (β-galactosidase) which
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hydrolyses lactose to glucose and galactose in order to be absorbed in the small intestine (Adams
& Moss, 1999; Sanders, 2000). About two-thirds of the world‘s population suffers from lactose
intolerance. These individuals do not possess this lactase (β-galactosidase) enzyme, and any
ingested lactose cannot be digested which leads to the gut microflora attacking the lactose. This
microbial attack occurs in the colon and produces abdominal discomfort, flatulence, and
diarrhea. However, when lactose intolerant individuals consume fermented milk products the
effects do not occur or are less severe. Researchers have found this to be due to the presence of
lactase in the probiotic products with incorporated lactic acid bacteria. The lactase is lysed by
bile when the bacteria reach the intestinal lumen, and acts on the lactose that has been ingested.
Thus relieving lactose intolerance symptoms (Tuohy et al., 2003).
Researchers observed significant decreases in small bowel lesions (associated with low
dose aspirin use) in a study of Lactobacillus casei as a treatment option. This inquiry and others
like it have led researchers to believe that daily consumption of probiotics can potentially aid in
gastrointestinal health against medications like aspirin. Amplified probiotic bacteria count in the
gut microbiota better equip individuals when medical drugs are administered on a daily basis.
The drugs will not diminish as many positive bacteria. Table 2 lists many commonly studied
probiotics and their associated health benefits.
2.3.2.1 Immunity
Probiotic testing has revealed promising results in the ability of the bacteria to enhance
immune responsiveness. The probiotic bacteria enhance immune responsiveness by
supplementing more beneficial bacteria to the preexisting microbiota of the host. The microbiota,
which is an active member of the intestinal defense, is charged with the responsibility of
maintaining immune responses, and sensitivity to potentially pathogenic bacteria. A LAB strain,
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Bifidobacterium lactisHN019, was recently found to enhance nonspecific immune functions.
―
Namely leucocyte (lymphocytes and phagocytes) proliferation, enhance phagocyte production
and proinflammatory cytokine production.‖ (Tuohy et al., 2003) Studies have also shown B.
lactis HN019 to increase peripheral blood leucocytes and natural killer cells in healthy
volunteers including the elderly; these attributes were observed to be active in the tumor and
viral destruction (Gill, Cross, Rutherfurd, & Gopal, 2001).
Dietary Lactobacillus rhamnosus HN001 has been investigated and proven in human
studies to enhance the natural immunity in consumers (Gill et al., 2001). Researchers also
suggested the use of the probiotic supplement in optimizing immune response in the elderly. L.
rhamnosus GG was also proven in its ability to improve immune response by way of preventing
atopic disease in high-risk children (Kalliomäki et al., 2008).
Other therapeutic applications of probiotics were observed by Rosenfeldt et al. who
demonstrated L. rhamnosus19070-2 and Lactobacillus reuteri DSM 122460 benefit in the
treatment of atopic dermatitis in children (Tuohy et al., 2003).
2.3.2.1.1 Probiotics augment gut barrier mechanisms
The intestinal barrier has a variety of components working in conjunction to protect the
body from infection as well as absorb key nutrients. As previously discussed the physical
components of the barrier such as the crypt depth, villi height and thickness of mucus are vital in
barrier function. The size as well as the surface area of villi determine the amount of nutrients
that are able to be absorbed (Yang et al., 2009). Larger surface area, allows larger amounts of
nutrients to be absorbed. Similarly, larger crypt depths are associated with improved digestive
efficacy (Guan, 2000). The crypts in the intestines are believed to facilitate digestion and
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absorption. Larger crypt depth means increased crypt cell number, thus increasing digestive
efficacy (Guan, 2000).
The importance of the microbial component of the barrier is seen in the absence of gut
microbiota, during which antigen transport is increased. Thus confirming the role of the gut
microflora in the defense barrier function (Tiihonen et al., 2010). Probiotic bacteria further
enhance this barrier function by increasing production of intestinal mucus, effecting tight
junction proteins, heightening the response of mucosal immunoglobulin A, introducing cellular
heat-shock proteins, as well as increasing stimulation of defensin production (Wallace et al.,
2011).
2.3.2.1.2 Functional Enzymes produced by Probiotics
Probiotic bacteria like Bifidobacteria have been known to stimulate the production of
enzymes such assecretory immunoglobulin A (sigA) in vitro; an enzyme influential in intestinal
barrier function. This enzyme inhibits invasion by pathogenic microbes and is an important
component of the intestinal immune system (Hanson, 1998). sIgA is produced by
immunoglobulin A plasma cells and forms the protective layer over the intestinal membrane
surface. Lactobacillus GG has also been found to increase numbers of sIgA and
immunoglobulin-secreting cells in the intestinal mucosa (Kalliomäki et al., 2008).
2.3.2.2 Cancer
The fight against cancer is a continual battle that has seen major advancements in the past
decade. New treatments and possible cures are constantly being searched for. Researchers have
found that probiotics help prevent the return of cancers like bladder and colorectal cancers
(Elliott, Summers, & Weinstock, 2005).
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Despite the fact that cancer can manifest in any individual, at any time, prevalent cases
do arise in the elderly population. Reports on colorectal cancer (CRC) specifically, indicate that
three-quarters of all incidences are random and the chance of getting this disease increases with
age (Tuohy et al., 2003). Although specific species have not been targeted as responsible, many
microorganisms in the gastrointestinal tract are capable of producing carcinogens and tumor
promoters from dietary content. This excludes Bifidobacteria and lactobacilli which do not
produce toxic or carcinogenic metabolites. A few species of the gut microorganisms that have
been identified as stimulating enzyme activity leading to the conversion of dietary products into
toxic or carcinogenic products such as β-glucuronidase, β-glycosidase, azoreductase,
nitroreductase, IO ‗hydratase-dehydrogenase‘ and nitrate/nitrite reductase, are clostridia and
bacteroides (Tuohy et al., 2003).
The consumption of probiotic bacteria acts to reduce the count of the potentially
pathogenic bacteria in the gut that produce toxins and carcinogens. In humans this reduced risk
of developing CRC has been proven, and human epidemiological studies have also suggested
that probiotics in the form of products such as yogurt, may reduce the risk of large adenomas in
the colon as well(Burns & Rowland, 2000).
Dietary factors are major contributors to the risk of cancers; diets high in fat and red,
processed, meat are associated with colon cancer (Bingham, 1999). Dietary factors that are
associated with reduced risk of cancer include high consumption of fruits, vegetables, whole
grain cereals, calcium, and fish (Bingham, 1999; Rafter & Glinghammar, 1998). Changes in the
metabolic activity and composition of the gut microbiota can potentially mediate the effect of
diet on the carcinogenic process. Bacteria of the microbiota could have roles in the initiation of
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colon cancer through production of carcinogens, cocarcinogens, or procarcinogens (Guarner &
Malagelada, 2003).
2.3.2.3 Obesity
In general, the long standing cause of obesity has been considered to be eating in excess,
and in some cases genetic predisposition accompanied by a lack of ample physical activity.
Mounting new evidence suggests the gut microbiota plays a role in the mechanism of the disease
of obesity. Research has associated gut microbiota with intestinal permeability, systemic
quantity of adipose tissue and body weight. The original link between gut microflora and weight
gain was a result of studies observing dietary fiber intake. In these studies decreasing dietary
fiber intake resulted in excess body weight and diabetes; the hypothesized cause of this result
was a change in gut microbiota due to an alteration in nutrient supply and digestion. However,
consumption of a high fat diet has been found to decrease the total number of bacteria in the gut
as well as promote the growth of gram-negative bacteria.
―
Four bacterial mechanisms have been identified to result in excess bodily energy gain:
(1) microbiota increase energy bioavailability by transforming increased proportions of nondigestible food into biochemically absorbable nutrients; (2) the influence of intrinsic bacterial
metabolism to generate and raise systemic levels of SCFAs to activate triglyceride synthesis; (3)
high fat diets can result in a responsive bacterial metabolism resulting in pathology (such as
microbial conversion of choline to methylamines leading to a choline deficient state, which
induces liver disease); and (4) the ability of the microbiome in regulating gut gene expression to
favor an obese state. Obese humans also demonstrate an alteration of the Firmicutes to
Bacteroidetes ratio that can be altered by weight loss.‖ (Ley et al., 2005; Ley, Turnbaugh, Klein,
& Gordon, 2006)
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2.3.3 Lactobacillus and Bifidobacterium
Lactobacillus and Bifidobacterium are members of a group of bacteria known as lactic
acid bacteria (LAB), and are from the phylum Firmicutes and Actinobacteria respectively. Lactic
acid bacteria (LAB) encompass gram positive, non-spore-forming, catalase-negative bacterial
species (Otieno, 2011). This group also includes Streptococcus, Enterococcus, Leuconostoc, and
Pediococcus (Mombelli & Gismondo, 2000). Most probiotics share an optimum growth
temperature of 37°C and optimum pH for initial growth is 6.5-7.0; although strains such as L.
casei prefer temperatures of 30 °C (Von Wright & Axelsson, 2011). Bifidobacteria are
taxonomically distant from lactic acid bacteria, but are grouped together because of the shared
metabolic end product, lactic acid; in addition they commonly share habitats, for example the
intestinal tract and dairy products (Ouwehand et al., 2002).
Lactobacilli are facultative anaerobes, gram positive, non-spore forming rods, they are
usually non-motile, catalase negative, and do not reduce nitrate. The genus Lactobacillus belongs
to the phylum Firmicutes, class Bacilli, order Lactobacillales, family Lactobacillaceae (Garrity,
Bell, & Lilburn, 2004). The population of Lactobacillus in the gastrointestinal tract includes a
variety of species and subspecies. Six species in particular are commonly isolated from humans:
L. acidophilus, L. salivarius, L. casei, L. plantarum, L. fermentum, and L. brevis (Mikelsaar,
Mändar, & Sepp, 1998). Lactobacilli strains are versatile and capable to adapting well because of
the diversity in the strains. Fermentation process, bacteriocin, and hydrogen peroxide production
vary among the strains.
Bifidobacteria are anaerobes (although there some species capable of tolerating oxygen),
also gram positive, non-spore forming rods, but possess a characteristic ―
Y‖ or club-shape
morphology. Up to 25% of the microorganisms in the gut are bifidobacteria. Nine species that

40
have been isolated from humans are B. bifidum, B. longum, B. infantis, B. breve, B. adolescentis,
B. angulatum, B. cantenulatum, B. dentium, and B pseudocatenulatum (Ballongue, Salminen, &
Wright, 1993).
―
These bacteria produce lactic acid, acetic acid, and propionic acid, which lower the
intestinal pH and suppress the growth of various pathogenic bacteria, thereby reestablishing the
balance of the gut flora.‖ (Alvarez-Olmos & Oberhelman, 2001; Doron & Gorbach, 2006).
2.3.3.1 Role of lactobacilli and Bifidobacteria in human health
The health promoting benefits of lactobacilli and bifidobacteria have been evident since
the early 1900s when the first reports were made. French scientist Tissier recommended treating
infantile diarrhea with large doses of bifidobacteria, and Nobel laureate Ilya Metchnikoff
suggested longevous effects from use of lactic acid bacteria of sour dairy products (Tissier,
1907).
Lactobacillus and Bifidobacterium are the two most common bacterial genera used in
probiotic products. Both bacteria can be found naturally in the gut microflora. The genera are
known to release short chain fatty acids which provide an energy source for the intestinal
membrane, promote intestinal epithelium repair, as well as improve the local blood supply (Yang
et al., 2009). Research thus far has provided evidence of the clinical effects certain probiotic
strains confer, such as Lactobacillus rhamnosus GG, L plantarum 299v, L casei, and L.
johnsoniiLa1; these strains aid in the treatment and/or prevention of intestinal origin (HamiltonMiller, 2004).
The value of lactic acid bacteria to human health revolves primarily around prevention
and treatment of gastrointestinal diseases. Examples of gastrointestinal diseases include irritable
bowel syndrome (IBS), infectious diarrhea, and inflammatory bowel disease (IBD). Irritable

41
bowel syndrome comes with an assortment of functional problems in the gut including,
constipation, intestinal pain, bloating, and diarrhea. An estimated 10% of the western population
has experienced symptoms of IBS (Ouwehand et al., 2002).Although the cause of IBS remains
unclear, species specific lactic acid bacteria have shown to improve symptoms (Ouwehand,
Kirjavainen, Shortt, & Salminen, 1999).
Infectious diarrhea is a gastrointestinal problem that has caused major concerns due to the
mortality in children. The source of diarrhea cases are often speculated, some believe the disease
to be caused by over population of pathogens in the gut with organisms like Clostridium difficile
and Klebsiellaoxytoca, during antibiotic treatment, thus altering the balance of the microflora
(Tuohy et al., 2003). Of the patients that receive antibiotics, 20% report cases of diarrhea (P
Marteau, Seksik, & Jian, 2002). ―
A recent meta-analyses has shown convincingly that
prophylactic consumption of lactic acid bacteria reduce the risk of antibiotic associated diarrhea,
Clostridium difficile associated diarrhea (Hempel et al., 2012), infectious diarrhea(Ritchie &
Romanuk, 2012), and necrotizing enterocolitis (AlFaleh, Anabrees, Bassler, & Al-Kharfi,
2011).‖
Although the use of lactic acid bacteria as a treatment of chronic diarrhea remain
inconclusive, indications of benefit in children have been found (Bernaola Aponte, Bada
Mancilla, Carreazo Pariasca, & Rojas Galarza, 2010). In cases of infantile diarrhea, often caused
by rotavirus, Lactobacillus rhamnosus GG has maintained a good track record of reducing the
duration of the diarrhea by about 50% (E. e. a. Isolauri, 1999). Although a mechanism has yet to
be clearly explained, possibilities of how probiotic bacteria stains alleviate diarrhea include
increasing mucosal integrity, and stimulating the immune response. In stimulating the immune
response, it would be key to target antirotavirus-specific immunoglobulin (Ig) A. Combinations
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of bacteria have also been used as in the case of Bifidobacterium bifidum and Streptococcuss
thermophilus, and have shown their ability to reduce incidence of diarrhea caused by rotavirus
(Saavedra, Bauman, Perman, Yolken, & Oung, 1994).
The gastrointestinal disease inflammatory bowel disease (IBD) is a group of disorders
with unknown cause. During IBD gut microflora is imbalanced and there are communication
issues which result in the immune system not recognizing the gut microbiota. Characteristically
patients suffer from chronic or reoccurring mucosal inflammation. There are two forms of IBD,
Crohn‘s disease and ulcerative colitis (UC). Lactic acid bacteria are being studied for their
ability to reduce the rate of relapse in UC (Sang et al., 2010). The mechanism by which probiotic
bacteria are believed to relieve symptoms and prevent recurrence is through regulation of the
inflammatory response or alteration of the composition of the gut microbiota (Tuohy et al.,
2003). One case of relief gained from probiotic bacteria is the nonpathogenic strain E. coli Nissle
1917, proven more effective in preventing relapse in Crohn‘s disease in patients versus a placebo
(Rembacken, Snelling, Hawkey, Chalmers, & Axon, 1999). S. boulardii has also shown some
success in relieving the symptoms of active Crohn‘s disease by reducing stool frequency and
disease activity, as well as reducing the risk of relapse(Guslandi, Mezzi, Sorghi, & Testoni,
2000).
The benefits of the consumption of probiotic bacteria are not limited to gastrointestinal
problems. Researchers have found that consumption of lactic acid bacteria reduces the infection
rate and duration of symptoms in the common cold (Hao et al 2011). Colds are usually cause by
viruses that escaped the immune system.
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2.3.4 Application of probiotics
The term probiotic is an umbrella term that encompasses foods, drugs, designer
probiotics, and direct-fed microbials (Sanders, 2009). Probiotic foods categorize food
ingredients, dietary supplements, and food itself. Probiotic drugs categorize supplements used for
their potential to prevent, treat, or cure disease. Designer probiotics categorize genetically
modified probiotics. Direct-fed microbials categorize probiotics intended for animal use.
Probiotic products can contain a single strain of a microorganism or a combination of several
species (Williams, 2010). Among the strains most commonly used, and incorporated into
products as probiotics include L. acidophilus and L. casei, due to their known health benefits.
Although lactic acid bacteria like Lactobacillus spp. and Bifidobacterium spp. are the
prevalent species used in dairy related probiotic products, other, non-lactic bacteria are also used.
These non-lactic strains are typically used in lyophilized or encapsulated ‗pharmaceutical‘ forms
(Holzapfel et al., 1998). Members of the non-lactic acid bacterial group include Bacillus and the
yeast Saccharomyces (Mombelli & Gismondo, 2000).
Of the commercially available probiotic products, many are not associated with scientific
studies to prove the legitimacy of the health claim offered. It is important to research the
products before consuming them. A few examples of products available that are tied to human
studies documenting efficacy include: (capsules) Culturelle, Fem-Dophilus, and Align;
(drinkable yogurt) Danimals; (yogurt) Activia and Yo-Plus; (powder) VSL #3 and Florastor;
(fermented milk) DanActive, and BioK+CL1285 (Douglas & Sanders, 2008).
2.3.4.1 Applications for the Elderly
Mounting evidence supporting the importance of gut microbiota homeostasis to human
health has led to the development of medical/ nutritional applications of probiotics targeted
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toward the elderly population (Biagi et al., 2012). Incorporating probiotics into the daily diet of
the elderly, or any individual seeking a healthier gastrointestinal system is a key aspect to
longevity. This integration of probiotics into the diet can take place by way of food products as
well as dietary supplements.
2.3.4.2 Dairy Products
One of the most common and historically documented medium for probiotic bacteria are
dairy products. Due to the natural properties of dairy products and the refrigerated temperatures
at which they are stored these products make suitable vehicles for probiotic bacteria(Song et al.,
2012). Dairy products containing probiotics commonly found on the market today include
yogurt, cheese, and sour and fresh milk. The probiotic microorganisms are adequately delivered
to humans because of the role dairy products play; providing an apt environment conducive of
growth and viability (Gardiner et al., 1999; Phillips, Kailasapathy, & Tran, 2006; Ross,
Fitzgerald, Collins, & Stanton, 2002; Saarela, Virkajärvi, Alakomi, Sigvart-Mattila, & Mättö,
2006).
2.3.4.3 Fruits and vegetables
Emerging new interest has arisen in the use of non-dairy products as vectors of probiotic
bacteria. The shift away from the traditional use of dairy goods derives from issues such as
lactose intolerance and high levels of cholesterol in currently available dairy food. Among the
requests from consumers as to new forms of probiotic products are vegetarian friendly products
(Heenan, Adams, Hosken, & Fleet, 2004). As a result a wider array of probiotic products are
being developed like fruits (Lavermicocca, 2006), vegetables (Yoon, Woodams, & Hang, 2006),
legumes (Heenan et al., 2004) and cereal products (Helland, Wicklund, & Narvhus, 2004).
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Delivering the probiotic bacteria to humans via fermented vegetables is possible, and this
substrate has been tested in a variety of forms as a potential vehicle for probiotics.
Table 2
Nontraditional vectors of probiotics.
Product

Bacterial strains

1. Vegetable derived
1.1 Tomato juice

L. acidophilus

1.2 Carrot juice
2. Fruit derived
2.1 Banana puree
2.2 Pomegranate

L. plantarum
L. casei
L. delbrueckii
Bifidobacterium strains

L. acidophilus
L. plantarum
L. delbruekii
L. paracasei
L. acidophilus
2.3 Orange juice
L. plantarum
2.4 Noni juice
B. longum
L. plantarum
2.5 Cashew apple juice
L. casei
3. Fruit and Vegetable mediums supporting various probiotic supplements
3.1 Apple juice
3.2 Beet juice
3.3 Cabbage juice
3. 4 Cranberry juice
3.5 Fermented banana
3.6 Fermented banana pulp
3.7 Ginger juice
3.8 Grape juice
3.9 Green coconut water
3.10 Passion fruit juice
3.11 Peanut milk
3.12 Pineapple juice
3.13 Probiotic banana puree
*Products available in the local market, in Greensboro, NC.

L. acidophilus
L. acidophilus
L. plantarum
L. plantarum
L. delbruekii
L. rhamnosus
L. acidophilus
L. acidophilus
L. rhamnosus
L. paracasei
L. plantarum
L. reuteri
L. plantarum
L. acidophilus
Bifidobacterium strains
L. casei
L. acidophlius
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4 2.4 Probiotic Supplements
There are a large number of probiotic products on the market today, and this number is
steadily increasing. Consumer interest in function food, including those containing probiotics,
has risen in the last 20 years (Song et al., 2012). Despite the predominant presence of probiotic
food products available to consumers, probiotic supplements are becoming more popular. The
Nutrition Business Journal 2011 reported that consumers spent 626 million dollars on probiotic
supplements in 2010 (Coulston & Boushey, 2013).
Probiotic dietary supplements are commercially available in the form of capsules,
gummies, liquids, powders, and tablets. Capsules are produced by manufacturers when a drug
cannot be compacted into a tablet; this form of the product also aids in swallowing problems.
Capsules are produced in soft and hard forms; 1) hard capsules are more commonly seen, they
are comprised of two halves fitted together and usually filled with a powder, 2) soft capsules are
comprised of a single piece, and are appropriate for oils etc. The technology for creating
products like these probiotic containing capsules has been developed to protect the bacteria from
damage during transit through the gastrointestinal tract.
Probiotics are also available in the convenience of liquids, ranging from on-the-go single
serving sizes to larger bottles for traditional dispensing. One benefit of the liquid probiotics is the
coating effect it can have on the gastrointestinal epithelium. The bacteria are applied directly to
the wall lining. This form of probiotic supplement does require refrigeration due to the presence
of active, live microorganisms. Those liquid supplements containing freeze-dried bacteria do not
require this refrigeration step.
Powders are another method of administering probiotics. These products cater more
towards individuals with difficulties swallowing capsules and tablets. The powder supplements
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can be incorporated into foods and/or beverages. Consumers must be mindful of the temperature
of the food or drink item they add the probiotic powder to, the supplement should not be added
to hot foods or drinks. It is important that these products be kept dry, and stored in a dark
location; moisture and oxygen can be destructive to probiotics.
A broader selection of probiotic supplements to choose from, in regards to forms,
benefits consumers and might increase the likelihood of purchase. The varieties of supplements
available provide improved convenience of quick and easy administration to confer the same
immune enhancing effects. Throughout history probiotics have been predominantly included in
dairy products; however with the increase in supplementation, consumers now have the ability to
choose between the two products to reap the health promoting benefits of probiotic bacteria.
The elderly population benefits from the convenience of multiple probiotic supplements
as well because the assortment of forms allows them to select a product that caters to their
mastication or swallowing abilities. Elderly with weak swallowing abilities are now able to
choose a liquid or powder form of a probiotic supplement for increased ease in administration.
The increase in probiotic supplementation means a rise in the number of products
available on the market. Probiotics, as previously mentioned encompasses many smaller
subgroups of products including probiotic food, probiotic drugs, specialty probiotics and
probiotic feed (for animals). The intended use of a probiotic agent determines its classification.
Probiotic drugs and dietary supplements have differing regulatory requirements to abide by. A
drug, defined by the Food and Drug Administration (FDA) is an article intended for use in the
diagnosis, cure, mitigation, treatment, or prevention of disease (Del Piano et al., 2006).
Probiotics intended for use as a drug, must go through the regulatory process as a drug.
Probiotics intended for use as a dietary supplement, however is considered a ―
food‖ and is
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regulated by the FDA‘s Center for Food Safety and Applied Nutrition (Philippe Marteau &
Seksik, 2004). This exclusivity in definition is necessary, and in particular in reference to this
study, due to the diversity among individuals being classified as elderly. This study is targeting
elderly individuals; this classification encompasses both healthy and unhealthy individuals.
Some consumers will have preexisting conditions that the probiotics might be able to reconcile in
addition to maintaining the microbial balance.
With the rise in probiotic supplements available commercially, it is vital for consumers to
research these products before making any general assumptions regarding probiotic use.
Currently there is no legal definition for the term probiotic, and products on the market labeled
―
probiotic‖ may not be equip with the distinguished characteristics of stability, content, or health
effects (Sanders, 2009). Researchers are adamantly testing the potential impact of probiotic
strains on a growing array of conditions and subjects. ―Agiven probiotic, tested in different
clinical situations, might exert a beneficial effect, show no effect, or result in an adverse effect.
However, a negative or adverse effect in certain situations does not negate probiotic status. Such
results do, however, stress the need to be specific about the benefits that are documented for each
probiotic and the situations in which use is considered to pose an undue risk.‖ (Sanders, 2009)
Consumers must also remember that probiotic supplements are intended to complement
the diet, and therefore should not be used as a replacement for probiotic microorganisms
provided through food consumption. Supplements alone are not sufficient, it is recommended for
individuals to balance their supplement and dairy probiotic intake.
2.4.1Viability of Probiotic cells in commercially available supplements
Viability of probiotic bacteria in commercially available supplements is crucial given that
these microorganisms must survive the shelf life of the product and the harsh environment of
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sections of the gastrointestinal tract, including an acidic stomach and enzyme and bile salt filled
small intestine (Vasiljevic & Shah, 2008). In order for probiotic supplements or products to exert
the health promoting effects claimed on the label, bacterial cells must remain viable up to human
consumption. Probiotic products, such as yogurt, often claim to contain bacterial counts of up to
several million live cells. Some researchers suggest that the minimum number of
microorganisms required to confer positive health effects are 8 log CFU/mL (Shah, 2000).This
large number of functional bacteria present during consumption ensures a sufficient amount of
the probiotic microorganisms reach the large intestine. The sensitivity of these microorganisms
to environmental conditions such as water activity, temperature, acidity, and redox potential
(presence of oxygen) can lead to the probiotic cells dying or being present in numbers lower than
advertised, at time of consumption; factors such as processing, storage, and time passed before
products are eaten(Siuta-Cruce, 2001; Vasiljevic & Shah, 2008).
Despite the importance of characteristics such as population count and viability in respect
to probiotics in commercially available products, very few studies have been conducted
substantiating the presence and quantity of probiotic bacteria claimed in many of the products on
the market. In 2006, Ibrahim and Carr conducted a study investigating the viability of
bifidobacteria in commercial yogurt products purchased in Greensboro, North Carolina and
found that only 44 out of the 58 commercial yogurt products (76%) tested contained viable
cultures (S. Ibrahim & Carr, 2006). Another aspect of the study observed the viability of
probiotic cells in the yogurt over time. In all tested samples bifidobacteria populations are nearly
undetectable by the fourth week, leading to the conclusion that consumers should wait no longer
than three weeks to consume probiotic containing yogurt. Similar results were found in the
earlier study by Coeuret et al. 2004, in which the quantity of Lactobacillus in probiotic feed and
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food products was examined (Coeuret, Gueguen, & Vernoux, 2004). Coeuret‘s research found
that in four of the products that claimed to contain probiotic bacteria the specified strains were
not detected. Additionally, five products mislabeled the number of bacteria present, and three
mislabeled the species of lactobacilli present. Investigation of probiotic supplement viability has
yielded results congruent to the probiotic food counterparts. In 2001 Temmerman et al. tested 30
dried probiotic supplements and found 11 contained no viable bacteria, 18 contained additional
species not identified on the label, and only 7contained all species claimed (Temmerman, Pot,
Huys, & Swings, 2003). These studies highlight the poor standard of probiotic supplements and
food products currently available for consumers. This issue is global, ‗similar reports of low
bacterial counts (zero in some cases), contamination, and unhelpful of misleading labeling of this
type of product on general sale in the USA (Alcid, Troke, Andszewski, & John, 1994; Gilliland
& Speck, 1977; Hughes & Hillier, 1990), Austria (Maurer, 1992; Shah, 2000), Italy (Canganella
et al., 1997; Hoa et al., 2000), and UK (Hamilton-Miller & Shah, 2002; Hamilton-Miller, Shah,
& Winkler, 1999).
Without reliable analysis of the microbial ingredients contained in probiotic products
companies cannot be held accountable for the claims they make on probiotic product labels.
Consumers are susceptible to mislabeling and consuming products lacking vital desired
ingredients. Additionally, there is major health concerns when results show products containing
species of bacteria not claimed on the label. Similar to validating studies conducted to support
the health benefits of the commonly used bacterial strains, the same accountability should be
applied to these probiotic food and supplement products. The need for current research is
apparent.
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Table 3
Classification of commercial probiotic supplements available in local stores.
Classification
1.

Capsule

2. Liquid

Example of Commercial Product

Probiotic strains

1.2 Digestive Advantage
1.3 Udo‘s Choice: Adult‘s Probiotic

Bacillus coagulansgbi
L. casei
L. rhamnosus
L. plantarum
L. acidophilus
L. bulgaricus
B. bifidum
Streptococcus thermophilus

1.3 Ultimate Flora 50 Billion

L. acidophilus
L. plantarum
L. rhamnosus
L. salivarius
L. bulgaricus
L. lactis
L. casei
B. bifidum
B. longum
B. breve

2.1 Probiotic Acidophilus Original

L. acidophilus
L. bulgaris
L. thermophulis
L. plantarum
L. rhamnosus
L. acidophilus
L. casei
L. salivarius
L. bulgaricus
B. longum
B. bifidum
B. lactis
Streptococcus thermophilus
L. casei
L. rhamnosus
L. acidophilus
B. bifidum
B. infantis

2.2 Keybiotics

2.3 Udo‘s Choice Probiotic (infant)

3. Powder
3.1 Primadophilus Reuteri

3.2 Jarro- Dophilus + FOS

L. acidophilus
L. rhamnosus
L. reuteri
L. casei
B. infantis
B. longum
L. rhamnosus
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3.3 Multidophilus Powder
4. Tablet

4.1 Twinlab: Time Release Probiotics

4.2 Flora Smart: Advanced Probiotic

4.3 Life Flora

L. acidophilus
L. plantarum
L. casei
B. longum
B. lactis
L. acidophilus
L. bulgaricus
B. bifidum
L. acidophilus
L. reuteri
L. plantarum
L. fermentum
B. bifidum
L. acidophilus
L. rhamnosus
L. salivarius
L. bulgaricus
L. plantarum
L. casei
B. bifidum
B. breve
B. longum
L. paracasei
B. longum
Streptococcus thermophilus
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2.4.1 Required Characteristics for Probiotics in supplements
The proven health and wellness benefits of probiotics have sparked rising interest from
consumers and the food industry within the past several years. Additional beneficial effects of
probiotics have been recognized in food preservation, specifically extension of shelf-life and
enhanced food safety (Gyawali & Ibrahim, 2012; Song et al., 2012). It is important that probiotic
bacteria possess two main characteristics, stability and functionality, in order to have practical
applications in probiotic supplements (Figure 3). Stability of probiotics is vital in maintaining a
high number of viable bacteria during processing and shelf-life. This is referred to as good
technological properties. Functionality of probiotics is related to their tolerance to low acid and
bile salts and their antimicrobial, adhesive, and enzyme activity. When incorporating probiotic
bacteria into supplements, other technological properties to consider are autolytic activity,
impact on sensory properties, and phage resistance. It is imperative to consider both
characteristics before selecting potential probiotics for use in supplements. It is equally important
to note that stability (cell viability) is not always enough to guarantee the probiotic functionality.

Figure 6 Requirement characteristics for probiotics in supplements.
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5 2.5 Composition of a longevous gut
In a study conducted in 2010 researchers investigated the gut microflora of centenarians
of Bama County in the Guangxi Zhuang Autonomous Region in China, famous for the longevity
of its population. The 2000 population census in China documented 76 centenarians living in
Bama County; the ratio was found to be 30.98 compared to the average ratio in Guangxi
province 4.44 centenarians per 1x 105 people (Zou, 2002). Researchers gathered bacterial species
from three groups of participants, the first group M the mean age was 98 years, group S the
mean age was 70 years, and group C the mean age was 82 years (Zhao et al., 2011).
Researchers found that the guts of many of the centenarian participants contained larger
numbers of Bifidobacteria in comparison to the young adults; notable due to elderly populations
typically possessing fewer Bifidobacteria (Suau et al., 1999). There were significant age related
differences in the bacterial species including Clostridium coccoides- Eubacterium rectal,
Bacteroides-Prevotella, and Clostridium perfringens all of which were found in the longevous
participants (Zhao et al., 2011). Bacteroides is an important group due to its role in the digestion
of polysaccharides in the cross-feeding network of the microbiota; they are also able to use an
array of carbon sources. The high levels of Bacteroides-Prevotella indicate a high level of
amlolytic activity in the colon of longevous people in Bama.‖ (Zhao et al., 2011)
6

2.6 Message to the public regarding medication
―
Improving the level of health among older people can—and must—be one of the aims of
modern gerontology, in order to decrease the rate of hospitalization, the administration of drugs
and, consequently, the healthcare cost of the ageing population.‖ (Biagi et al., 2012) The
aspiration of this study is not to deter elderly individuals from taking their medication, but to
inform them that it is vital to replace the bacteria they lose due to their consumption of the
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medication. Maintaining a healthy gut is easily achieved through the incorporation of probiotic
products in the diet. Probiotics consumed daily will significantly increase the number of good
bacteria in the gut microbiota. By increasing this microbiota composition positively elderly hosts
have a larger number of bacteria when consuming medical drugs. Therefore when the drugs do
disrupt the microbiota there is still a large probiotic population remaining. Individuals
consuming probiotic products sparingly and inconsistently are not equip with such large numbers
of good bacteria in the gut. Therefore when the drugs wipe the good bacteria out of the gut
microflora the individual might suffer from more gastrointestinal issues.
When searching for probiotic supplements to take consumers should be mindful of the
labeling of these products. Labels of probiotic supplements should include: notification of the
presence of live bacteria, the exact nature of the bacteria, identification of species present
specifically numbers of each species (this should be explained in terms understandable by
consumers, yet microbiologically accurate), minimum amount of bacteria require to confer
health effects (either in terms of numbers of bacteria or servings), and accurate content at the
time of purchase (not simply at some stage of manufacture). Consumers need to inquire about
probiotic supplements with a specific benefit in mind in order to find an appropriate probiotic to
cater to that need.
7

2.7 Justification
Numerous studies have shown the impact of probiotics on human health, and have
demonstrated that Bifidobacterium and Lactobacillus strains can positively impact health. It is
proven that probiotic bacteria are involved in immune modulation and strengthening the gut
mucosal barrier (Ouwehand et al., 2002). Mechanisms by which these microorganisms
accomplish this include gut microflora modification, intestinal mucosa adhesion and facilitation
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of the prevention pathogen attachment or pathogen activation, modification of dietary proteins
by the intestinal microflora, alteration of bacterial enzyme function, and influence of gut
mucosal permeability(Ouwehand et al., 2002). Probiotics benefit individuals of all ages, and age
specific probiotic choices are available. The health conferring microorganisms are commercially
available to consumers in many products including probiotics supplements. These supplements
come in forms such as capsules, liquids, powders, and tablets. The elderly population is often
targeted to consume probiotics by the researchers due to the natural decrease of ―
good‖ bacteria
in their gut microbiota with increasing age; as well as the increase incident of elderly taking
medication.
Advanced age is typically accompanied by a decrease in health. As health issues arise in
the elderly population, medications are vital for treatment. Interactions between medications and
functions of the body have been well studied. There are also many reported adverse effects
associated with the drugs commonly prescribed to elderly patients; negative impact on the
gastrointestinal tract physically and alteration of the microbial balance are two of significance.
The most common adverse effect of non-steroidal anti-inflammatory drugs is damage to the
mucosa of the gastrointestinal tract (Bjarnason, 2009). Other side effects include gastric pain,
heartburn, nausea, vomiting, bleeding, perforation, and ulceration (Zeino et al. 2010). A major
medication of concern is aspirin, a non-steroidal anti-inflammatory drug or NSAID. NSAID
drugs are linked to gastric and duodenal damage (Bjarnason & Takeuchi, 2009; Laine, 1996; Soll
et al., 1991). The more common locations effected by adverse reaction of drugs are the small and
large intestine, which represent 20 to 40 percent of drug side effects (Zeino et al., 2010).
Due to the interaction of medical drugs and functions of the body, there might be a
similar interaction of medical drugs and naturally occurring probiotic bacteria of the gut
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microbiota. There is limited research in this area; therefore with this justification further study
must be conducted. This project is aimed to study the effect of drugs commonly taken by the
elderly population, on viability and functionality of probiotics strains found in commercially
available probiotic supplements.
8 2.8 Objectives
The specific aims of this investigation are:
1) To examine the viability of probiotics in commercial dietary probiotic supplements
available in local stores.
2) To determine the impact of aspirin and caffeine on the functionality of a probiotic
supplement. In this project, functionality was determined by performing: (a) β- galactosidase
activity, (b) bile resistance, (c) reducing power, and (d) protein expression.
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9 CHAPTER 3
Materials and Methods
3.1 Objective 1
This objective will examine the viability of probiotics in commercial probiotic
supplements.
3.1.1 Materials
3.1.1.1 Probiotic supplements
Ten probiotic supplements were purchased from a local health store in Greensboro North
Carolina. Each of these supplements claimed to include various strains of bifidobacteria (B.
longum, B. bifidum, B. lactis, B. breve, B. infantis) and lactobacilli (L. acidophilus, L.
rhamnosus, L. reuteri, L. gasseri, L. plantarum, L. casei, L. brevis, L. salivarius, L. paracasei)
(seen in the table below).
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Table 4
Composition of commercial probiotic supplements (by strain).

Supplement Number

Commercial Name

Probiotic strains

Form

1.

Culturelle

L. GG

Veggie Capsule

2.

(Natren) Megadophilus

L. acidophilus

Veggie Capsule

3.

(Solaray) Multidophilus

L. acidophilus
L. bulgaricus
B. bifidum

Veggie Capsule

4.

(Klaire Labs) Ther- biotic Factor 4

B. bifidum

Veggie Capsule

5.

(Nature‘s Way) Primadophilus Reuteri

L. rhamnosus
L. acidophilus
L. reuteri (HA- 188)

Veggie Capsule

6.

(Pure Encapsulations) Lactobacillus

L. acidophilus (LA-5)

Capsule

Acidophilus
7.

(Bluebonnet) Acidophilus Plus FOS

L. acidophilus

Veggie Capsule

8.

(Life Extension) Bifido GI Balance

B. longum (BB536)

Veggie Capsule

9.

Kyo- Dolphilus 9

L. gasseri B
L. gasseri M
L. rhamnosus
B. bifidum
B. longum M
B. infantis
B. breve
B. lactis

Capsule

10.

(Garden of Life) Primal
Defense: HSO Probiotic
Formula

L. plantarum
L. rhamnosus
L. casei
L. brevis
L. salivarius
L. acidophilus
L. paracasei
B. lactis
B. bifidum
B. breve
B. longum
Bacillus subtilis

Veggie Capsule
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3.1.1.2 Chemicals and Media
Three growth media were used to cultivate the probiotic bacteria listed on the commercial
supplement labels. MRS agar (deMan, Rogosa& Sharpe) was used for all Lactobacillus and
Bifidobacterium strains, and was prepared following the manufactures recipe. Modified BIM 25
was used for Bifidobacterium strains. The medium contained the following ingredients (gram per
liter): MRS broth 55; Agar 20; Nalididixic acid 0.02; Polymyxin B sulphate 0.0085;
Kananycinsulphate 0.05; Iodoacetic acid 0.025; 2,3,5-triphenyltetrazolium chloride 0.025;
cysteine-hydrochloride 0.5; lithium chloride 1.5; beef extract 1.0; and Tween 20 5mL (S. A.
IBRAHIM & SALAMEH, 2001). Reinforced Clostridium Agar (RCA) with bromocresol green
and clindamycin (RCABC) was prepared following the methods of Darukaradhya et al. 2006
(Darukaradhya, Phillips, & Kailasapathy, 2006).

61
Table 5
Commercial probiotics supplements and corresponding selective and differential media.
Supplement Number

Probiotic strains

1.

L. GG

MRS

2.

L. acidophilus

MRS
RCA

3.

L. acidophilus
L. bulgaricus
B. bifidum

MRS
BIM 25
RCA

4.

B. bifidum
B. longum
B. lactis
B. breve

MRS
BIM 25

5.

L. rhamnosus
L. acidophilus

MRS
RCA

L. reuteri (HA- 188)
L. acidophilus (LA-5)
L. acidophilus
L. bulgaricus
B. bifidum
B. longum

RCA
MRS
BIM 25
RCA

6.
7.

8.

B. longum (BB536)

9.

L. gasseri B
L. gasseri M
L. rhamnosus
B. bifidum
B. longum M
B. infantis
B. breve
B. lactis

10.

L. plantarum
L. rhamnosus
L. casei
L. brevis
L. salivarius
L. acidophilus
L. paracasei
B. lactis
B. bifidum
B. breve
B. longum
Bacillus subtilis

Selective and Differential Media

MRS
BIM 25
MRS
BIM 25
RCA

MRS
BIM 25
RCA
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3.1.2 Methods
3.1.2.1 Sample Preparation
Samples were prepared by adding two capsules of each supplement into individual tubes
of fresh MRS broth, and then mixed for 15 to 30 s using a vortex. The ten probiotic cultures were
incubated for 12-14 h at 37°C, for the recovery of the cells. Overnight cultures were then used to
test for viability and functionality of each probiotic supplement.
3.1.2.2 Viability of bacterial cells
Probiotic cultures were serially diluted in 9 ml of sterile 0.1% peptone water, and then
appropriate dilutions (100 µl) were transferred onto the respective agar. Appropriate dilutions
were surface plated in duplicate on Lactobacilli MRS (Difco, Detroit, MI, USA) for enumeration
of Lactobacillus strains. Modified BIM-25 was used for the enumeration of bifidobacteria(S.
Ibrahim & Carr, 2006). Reinforced Clostridium Agar with bromocresol green and clindamycin
(RCABC), which is a non-selective media used for the growth of Lactobacillus acidophilus spp.,
and Reinforced Clostridium Agar with aniline blue and dicloxacillin (RCAAD), which is
differential for Bifidobacterium spp. was also be used (Darukaradhya et al., 2006). The plates
will be incubated for 72 h at 37°C. Plates containing 25-250 colonies will be counted to calculate
bacterial populations.
3.1.2.3 β- Galactosidase Activity
The activity of β-Galactosidase was quantified using the o-nitrophenyl-β-D-galactoside
(ONPG) assay as described by Miller (J. Miller, 1993).Cultures were first grown to mid log
phase, and an initial O.D. was measured. The cultures were incubated at 37°C until an O.D. of
0.7-0.9 (nm) was observed. A 100 µl aliquot of starter culture was washed, and 900 µl of Z
buffer (composed of 0.06M Na2HPO4; 0.04M NaH2PO4; 0.01M KCl; 0.001M MgSO4*7H2O)
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was added to the pelleted bacterial cells and washed a second time. Chloroform was then added
at 10µL per tube and samples were mixed by vortex for 10 s. The mixture was incubated at 37
°C on a shaker with caps removed for 30 min. After incubation, 200 µl of β-ONPG(4 mg/ml in
0.1 M phosphate buffer) was added to each tube and vortex in order to start the reaction. The
reaction was stopped by adding 0.5 mL of 1N Na2CO3 (10.6g/100ml) after the expected yellow
color had developed. The time taken for the color to be developed in each tube was recorded.
Optical density was recorded at OD420 and OD550. Unit of β-gal produced was calculated as
follows:
Unit of β-gal = 1000 (OD420- 1.75 * OD550)
t * v * OD610nm
Units of β-gal were calculated as described by Miller (S. Ibrahim & O'Sullivan, 2000; J.
Miller, 1993).
3.2 Objective 2
The objective of this investigation was to determine the interaction between one commercial
probiotic supplement, and commonly administered medical drugs of elderly people.
Additionally, investigation of the interaction between the supplement and caffeine conducted.
3.2.1 Population
The probiotic supplement 5, obtained from the local market will be tested in this
investigation (Table 4). The supplement was initially be cultured in MRS broth in anaerobic
culture tubes at 37°C for18 h.
3.2.2 Determination of β- galactosidase activity
The activity of β-Galactosidase was quantified using the o-nitrophenyl-β-D-galactoside
(ONPG) assay as described by Miller (J. Miller, 1993). Cultures were first grown to mid log
phase, and an initial O.D. was measured. The cultures were incubated at 37°C until an O.D. of
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0.7-0.9 (nm)was observed. A 100 µl aliquot of starter culture was washed, and 900 µl of Z buffer
(composed of 0.06M Na2HPO4; 0.04M NaH2PO4; 0.01M KCl; 0.001M MgSO4*7H2O) was
added to the pelleted bacterial cells and washed a second time. Chloroform was then added at
10µL per tube and samples were mixed by vortex for 10 seconds. The mixture was incubated at
37 °C on a shaker with caps removed for 30 minutes. After incubation, 200 µl of β-ONPG (4
mg/ml in 0.1 M phosphate buffer) was added to each tube and vortex in order to start the
reaction. The reaction was stopped by adding 0.5 mL of 1N Na2CO3 (10.6g/100ml) after the
expected yellow color had developed. The time taken for the color to be developed in each tube
was recorded. Optical density was recorded at OD420 and OD550. Unit of β-gal produced was
calculated as follows:
Unit of β-gal = 1000 (OD420- 1.75 * OD550)
t * v * OD610nm
Units of β-gal were calculated as described by Miller (S. Ibrahim & O'Sullivan, 2000; J.
Miller, 1993).
3.2.3 Bile Resistance
The effects of bile on the growth of LAB cells will be conducted by a method modified
from those of Gilliand and Walker and Yu and Tsen (Gilliland & Walker, 1990; Yu & Tsen,
1993). After drug treatment, the surviving LAB cells were collected by centrifugation (7000 rpm,
5 min) and washed once with PBS (pH 7.2). The cells will be resuspended in 10 ml MRS broth
with or without 0.3% (w/v) ox gall bile (Sigma; Louisiana, USA) and incubated at 37ºC for 48 h
under anaerobic conditions. Bile tolerance of the LAB cells was determined by comparing the
viable LAB counts on MRS agar. Each assayed will also be performed in duplicate (Lin, Hwang,
Chen, & Tsen, 2006).
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3.2.4 Reducing Power Assay
The reducing power of probiotic supplements was determined according to the method
reported by Mau et al. 2004. Supplement 5 (1.0 ml) was mixed with 2.5 ml sodium phosphate
buffer (pH = 7.4, 0.02 M) and2.5 ml potassium ferricyanide (1.0%, w/v). This mixture was then
incubated at 50 °C for 20 min. After, 2.5 ml of trichloroacetic acid (10.0%, w/v) was added to
the mixture to terminate the reaction. The mixture was centrifuged at 200g for 10 min. The upper
layer (5 ml) was mixed with 5 ml of deionized water and 1 ml ferric chloride (0.1%, w/v). The
absorbance was measured at 700 nm. A higher absorbance of the reaction mixture indicates a
higher reducing power.
3.2.5 SDS Gel
Cell extraction procedure was performed as described by Thermo Scientific: B-PER
Bacterial Protein Extraction Reagent. Bacterial cells were pelleted by centrifugation at 5000 × g
for 10 min. B-PER Reagent was added at 4mL per gram of cell pellet. The suspension was
pipetted up and down until it is homogeneous. When homogeneity was reached the sample was
incubated for 10-15 min. at room temperature. The lysate was centrifuged at 15,000 × g for 5
minutes to separate soluble proteins from the insoluble proteins.
BCA was performed as described by Thermo Scientific: Pierce BCA Protein Assay Kit.
First standards and working reagent were prepared. Diluted Albumin (BSA) Standards were
prepared using the table provided by Thermo Scientific. The contents of one Albumin Standard
(BSA) were diluted into several clean vials, preferably using the same diluent as the sample(s).
Each 1mL ampule of 2mg/mL Albumin Standard is sufficient to prepare a set of diluted
standards for either working range suggested in the table. There will be sufficient volume for
three replications of each diluted standard. The BCA Working Reagent (WR) required the use of
the following formula to determine the total volume of WR required.
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(# standards + # unknowns) × (# replicates) × (volume of WR per sample) = total volume WR required.

Once the standards and working reagent were prepared 0.1mL of each standard and
unknown sample replicate was pipetted into an appropriately labeled test tube. WR (2 mL) was
added to each tube and was mixed by vortex. Tubes were incubated at 37°C for 30 minutes.
With the spectrophotometer set to 562nm, the instrument was zeroed using a curette filled only
with water. The absorbances of all the samples were measured within 10 minutes.
The average 562nm absorbance measurement was subtracted from the blank standard replicates
from the 562nm absorbance measurement of all other individual standard and unknown sample
replicates. A standard curve was prepared by plotting the average blank-corrected 562nm
measurement for each BSA standard vs. its concentration in µg/mL. This standard curve was
used to determine the protein concentration of each unknown sample.
SDS Page. The polyacrylamide gel was prepared according to standard protocol. Samples
were loaded, and the gel was run at 25 mA in 1x SDS Running Buffer. The gel was then stained
and placed in a plastic container. The gel was then covered with isopropanol fixing solution and
shaken at room temperature. For 0.75 mm-thick gels, shake 10 to 15 min; for 1.5 mm thick gels,
shake 30 to 60 min. After appropriate shaking time the fixing solution was poured off. The gel
was then covered with staining solution and shaken at room temperature for 2 hours. The
staining solution was poured off and the gel was washed with 10% acetic acid.
10

11

67
12 CHAPTER 4
Results
4.1 Objective 1
In this study we used commercial probiotic supplements available in the market to
determine the viability of bacterial cells. These supplements were divided into three groups
based on the type of bacterial population (Lactobacillus spp., L. acidophilus, Bifidobacterium
spp.). Table 6 shows the initial population of probiotic cultures found in ten commercial dietary
supplements. The initial bacterial populations of group 1, Lactobacillus spp., ranged from 5.39 to
9.39 log CFU/ml. Supplement 8 exhibited the lowest number at 5.39 ± 0.00 log CFU/ml.
Supplement 1 exhibited the highest number at 9.39 ± 0.00 log CFU/ml. The initial bacterial
populations of group 2, L. acidophilus, ranged from 5.63 to 8.81 log CFU/ml. Supplement 10
exhibited the lowest number at 5.63 ± 0.21 log CFU/ml. Supplement 2 exhibited the highest
number at 8.81 ± 0.06 log CFU/ml. In group 3, Bifidobacterium spp., the initial bacterial
populations ranged from 4.38 to 7.86 log CFU/ml. Supplement 8 exhibited the lowest number at
4.38 ± 0.00 log CFU/ml. Supplement 9 exhibited the highest number at 7.86 log CFU/ml. The
initial population count indicates the presence of probiotic bacteria in all tested supplements as
claimed on the label.
Table 6 also shows the changes in the viability of bacterial cells present in the
supplements after 4 weeks in refrigeration storage (4°C). Viability post storage period in group 1
ranged from 5.27 to 9.10 log CFU/ml. Supplement 10 exhibited the lowest presence at 5.27
±0.14 log CFU/ml, whereas supplement 1 exhibited the highest presence at 9.10 ± 0.04 log
CFU/ml. Viability post storage period in group 2 ranged from 4.34 to 7.89 log CFU/ml.
Supplement 10 exhibited the lowest number at 4.34 ± 0.16 log CFU/ml, and supplement 9
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exhibited the highest number at 7.89 ± 0.26 log CFU/ml. viability post storage period in group 3
ranged from 4.08 to 7.55 log CFU/ml. Supplement 10 exhibited the lowest population count at
4.08 ± 0.09 log CFU/ml. Supplement 9 exhibited the highest population count at 7.55 ± 0.19.
A comparison of viability pre- and post storage period reveals a reduction in bacterial
population count. The maximum reduction in group 1 was found to be 3 log CFU/ml
(Supplement 6), followed by 1 log CFU/ml (Supplement 2, 7, 10). All other supplements
exhibited reductions ≤ 1 log CFU/ml (Supplements 3 and 9). The maximum reduction in group 2
was found to be 2 log CFU/ml (Supplement 6), followed by 1 log CFU/ml (Supplement 2). All
other supplements exhibited reductions ≤ 1 log CFU/ml (Supplements 1, 3, 5, 7, 9, and 10).The
maximum reduction in group 3 was found to be ≤ 1 log CFU/ml (Supplements 5, 7, 9, and 10).
One supplement, however, did demonstrate ≤1 log CFU/ml increase (Supplement 3).
A few supplements were able to maintain their initial population count after the storage
period (Supplements 1, 4, 5, 78, and 10). Post storage viability indicates an increased likelihood
of supplement capability to exert health-promoting effects as claimed on the label, up to human
consumption. Supplements 1, 5, and 7 each exhibited population counts that are maintained and
met the required 8 log CFU/mL minimum. Supplements 4, 8 and 10, however, maintained their
initial population count but do not meet the suggested minimum 8 log CFU/mL of
microorganisms required to confer positive health effects. Based on the label description
supplements 4, and 8 should contain 10+ and 2 billion CFUs respectively. Supplement 10 did not
claim a CFU amount on the label. This large number of functional bacteria present during
consumption ensures a sufficient amount of the probiotic microorganisms reach the large
intestine.
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Table 6
Bacterial population in different types of supplements during refrigeration storage (4° C) for 4
weeks.

4.1.2 β- Galactosidase (β-gal) Activity
Table 4.2 shows the β –gal activity of the ten commercial probiotic supplements both in
the presence of glucose (uninduced) and lactose (induced). The mechanism of this color change
can be seen in Figure 4.1 below. It involves the breakdown of ONPG (colorless) into galactose
(colorless) and o-Nitrophenol (yellow). The bright yellow color signifies the breakdown of
lactose; increasing intensity of the yellow color indicates increasing β-gal activity (Figures 4.2
and 4.3). The activity of β-gal in the uninduced group, control, ranged between 26and 860 Miller
unit/mL, and activity in the induced group ranged from 160to 1,120 Miller unit/mL. The average
β- gal activity of the control samples was 170 Miller units. The induction of probiotic
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supplements with lactose increased the average β- gal activity. Lactose acted as a carbohydrate
source on the induction of β-gal activity. Notable increases from uninduced to induced enzyme
activity include: Supplement 5, 50 to 1,120 Miller units; Supplement 6, 28 to 1,068 Miller units;
and Supplement 8, 26 to 1,065 Miller units. Two supplements exhibited minor increases, but
maintained relatively high β-gal activity levels. Supplement 3, 860 to 885 Miller units; and
Supplement 4, 700 to 715 Miller units. Supplements 5 exhibited the strongest enzyme activity at
1,120 Miller units. Supplement 10 exhibited the lowest enzyme activity at 1.45 Miller units.
Supplements exhibiting the lowest enzyme activity and lowest increase from uninduced to
induced include: Supplement 1, 0.80 to 15 Miller units; Supplement 7, 12 to 160 Miller units;
and Supplement 10, 0 to 1.45 Miller units.

Figure 7 Mechanism of β-galactosidase.
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Table 7
β -galactosidase activity in commercial probiotic supplements.

β- Galactosidase activity (Miller units)
Supplements

Uninduced

Induced

Supplement 1
Supplement 2
Supplement 3
Supplement 4
Supplement 5
Supplement 6
Supplement 7
Supplement 8
Supplement 9
Supplement 10

0
0
860
700
50
28
12
26
5
0

15
775
885
715
1,120
1,068
160
1,065

6
1

Figure 8 (left) β -gal activity in the presence of glucose (uninduced). (right) β -gal activity in the
presence of lactose (induced).
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4.2 Objective 2
Since Supplement 5 demonstrated viability and maintained viability during refrigerated
storage, it was chosen for additional experiments in objective 2. In this objective we attempt to
understand the impact of aspirin and caffeine on the functionality of a probiotic supplement. In
this project, functionality was determined by performing: (a) β- galactosidase activity, (b) bile
resistance, (c) reducing power, and (d) protein expression.
4.2.1 Exposure to aspirin and caffeine
In the experiment an aspirin stock composed of 1 gram of aspirin and 10 mL of Dimethyl
sulfoxide (DMSO) was prepared to determine the impact of aspirin on the supplement. After a 12
h growth period at 37°C the supplement was serially diluted in 9 mL of peptone water. Then
100µl of aspirin stock was added to each dilution and incubated for 2 h at 37°C. The exposure of
Supplement 5 to aspirin resulted in a population decrease from 8.95±0.14 to 2.20±3.10 log
CFU/mL. When bacterial cells exposed to caffeine there was a slight decrease to 8.72±0.04 log
CFU/mL.
4.2.2 β- galactosidase (β- gal) activity
The effect of aspirin and caffeine on the β-gal activity of a probiotic supplement
(Supplement 5) was determined. The levels of β-gal activity varied dependent on the exposure to
caffeine or aspirin. After 2 h of incubation, enzyme activity of supplement 5 can be seen in Table
4.3 Supplement 5 exhibited an increase to 1090 Miller units compared to the control at 500
Miller units after being exposed to caffeine. Supplement 5 treated with aspirin showed a
significant decrease in activity, declining to 62 Miller units.
Additionally, we determined the effect of aspirin on supplement 5 at progressively lower
inoculums. The initial β-gal was 697.5 Miller units, while the first inoculum level demonstrated
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an increase to 1629.5 Miller units, each subsequent dilution factor decreased in enzyme activity.
These results are consistent with research that stresses the importance of probiotic consumption
in order to replenish or sustain the level of beneficial bacteria in the microbiota. The higher
inoculum levels did not exhibit significant enzyme activity decreases after exposure to aspirin
compared to lower inoculum levels which demonstrated weaker enzyme activity post aspirin
exposure.
The increase of β-galactosidase after exposure of caffeine can be contributed to the
hydrolysis of the cell membrane by caffeine. Caffeine allows the enzyme to be released in the
media, whereas aspirin inhibits protein synthesis.

Table 8
(a) Supplement β- gal activity post aspirin and caffeine exposure. (b) β – gal activity in
decreasing inoculum levels.

(a) β- Galactosidase activity (Miller units)
Treatment

Uninduced

Induced

Control
Caffeine
Aspirin

100 ± 84
162 ± 32
51 ± 18

500 ± 42
1090 ± 287
62 ± 79

(b) β-Galactosidase activity in decreasing inoculum levels (Miller units)
Dilution Factor

Uninduced

Induced

Control
-1
-2
-3

162.5
200
87.5
6

697.5
1629.5
319.5
190.5
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Figure 9 (left) β- gal activity after exposure to aspirin and (right) after exposure to caffeine.

Table 9
β-gal activity post exposure to 3% bile.

β- Galactosidase activity (Miller units)
Treatment

Induced

Uninduced

Control
Bile

486 ± 122
780 ± 290

52 ± 60
327 ± 10

We also evaluated the effect of bile (3% w/v) on the β-gal activity of supplement 5. An
incubation period of 2 h resulted in an increase of supplement enzyme activity as seen in Table
4.4. Supplement 5 exhibited an increase to 780 Miller units compared to the control at 486 Miller
units after being exposed to bile (3% w/v). Similar studies of the effect of bile on β-gal activity
also found the activity to be greater if bile was included in the medium. Zarate et al. 2000
observed the β-gal activity enhancement of P. acidipropionici in the presence of bile salts due to
the permeabilization of the cells during the first hour of exposure (Zárate, Chaia, González, &
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Oliver, 2000). These effects have also been demonstrated in lactobacilli species (De Valdez et
al., 1997; Noh & Gilliland, 1993).

Figure 10 β-gal activity after exposure to bile (3%).

4.2.3 Bile resistance
The survival of Supplement 5 in the presence of bile (3% w/v) was determined. The
initial population was 9.14 ± 0.09 log CFU/mL. Post exposure the population slightly decreased
to 8.99 ± 0.04 log CFU/mL.
Following survival, bile resistance was investigated. After drug treatment, the surviving
LAB cells from supplement 5 were resuspended in 9 mL MRS broth with or without 3% (w/v)
bile. Table 4.5 shows the bile resistance of the probiotic supplement after exposure to aspirin.
The decreasing dilution factors represent the decrease in bacteria population in the presence of
consistent amounts of aspirin (100 µl). Resistance to bile is an important property for probiotic
strains.
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Table 10
Bile resistance of probiotic supplement after exposure to aspirin.
Bile Resistance (log CFU/mL)

Control
Treatment (aspirin)

Bile (3% w/v) Exposure

No Bile Exposure

7.88 ± 0.26
5.63 ± 0.15

7.98 ± 0.55
5.48 ± 0.28

4.2.4 Reducing power
Antioxidant properties were assayed in terms of antioxidant activity (AOA) by reducing power.
The behavior of strains found in Supplement 5 in was determined by measuring changes in the
absorbance at 700 nm for cultures exposed to caffeine and aspirin. The reducing power of
supplement 5 was 0.39.

Figure 11 Reducing power to probiotic supplement. (Left: blank; right: supplement)
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4.2.5 Protein expression
The effect of aspirin and caffeine on the protein expression of supplement 5 was
examined. First protein concentration was established. Protein concentration detects total
protein. Figure 12 shows protein concentration of supplement 5. There was a decrease in protein
concentration from 836.21 µg/ml (control) to 547.59 µg/ml after exposure to aspirin. Similarly,
when the supplement was exposed to caffeine, protein concentration decreased from
836.21µg/ml (control) to 652.13 µg/ml.

Figure 12 Protein concentration of supplement exposed to aspirin and caffeine.
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Figure 13 Protein expression (Silver stain)

The result of total protein was confirmed with a gel. From left to right, Figure 13 shows lanes
containing the 1) marker, 2) control cells, 3) aspirin treated cells, 4) caffeine treated cells, 5)
control supernant, 6) aspirin treated supernant, 7) caffeine treated supernant, 8) control mix, 9)
aspirin treated mix, and 10) caffeine treated mix. For explanatory purposes, these samples were
grouped into 3 categories. Samples 2 to 4 were grouped as I, characterized by the protein source
being the pelleted bacterial cells. Samples 5 to 7 were grouped as II, characterized by the protein
source being the supernant. Samples 8 to 10 were grouped as III, characterized by the protein
source being a mixture of the supernant and pelleted cells.
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Protein expression of Supplement 5 (Figure 13), was markedly affected when treated with
aspirin in comparison to treatment with caffeine and the control. Aspirin was found to inhibit
individual proteins. Observations indicate that in group I, 9 groups are present in sample 2, 7
groups are present in sample 3, and 8 groups are present in sample 4. In group I the lower profile
is absent in both aspirin and caffeine treatments. Group III shows 6 groups are present in the
sample 8, 3 groups are present in sample 9, and 3 groups are present in sample 10. The number
of observable bands was lower than in untreated samples.
In terms of observable total bands as individuals from group I, sample 2 has 15 bands,
sample 3 has 8 bands, and sample 4 has 10 bands. From group III, sample 8 has 6 bands, sample
9 has 3 bands, and sample 10 has 3 observable total bands.
The molecular weight of the probiotic bacteria are lower than 250 kD, which was to be
expected. The effect of aspirin and caffeine were different; aspirin had effect on the lower bands
and caffeine affected the lowest band the most. Proteins were only detected in samples
containing cells; it was these proteins that treatment affected. The supernant demonstrated no
protein presence.
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13 CHAPTER 5
Discussion and Future Research
In this project, we have two objectives which were to determine: (a) the viability of
probiotics in commercial probiotic supplements in laboratory medium by surface plating and
measuring β- galactosidase activity, and (b) the interaction between probiotic supplements and
commonly administered medical drugs of elderly people, and commonly consumed caffeine.
The first experiment of Objective 1, we determined bacterial populations by counting
CFU/ml after 24 hr incubation at 37°C. Ten commercial dietary supplements were surface
plated on selective and/or differential media based on their probiotic content. Viability was
demonstrated via presence upon surface plating on respective media, thus confirming the
presence of bacterial populations claimed on the supplement labels. Declines in population were
observed in a few supplements after the storage period of four weeks. Our results indicate that
storage, even as directed by labels, impacts the viability of probiotics in commercial dietary
supplements. Ibrahim and Carr (2006) reported, similarly, that probiotic cultures in commercial
yogurt brands were not viable after 3-4 weeks of storage at 4°C.Increasing knowledge on the
effects storage has on probiotic products is a crucial aspect of ensuring health benefits are
conferred. Functionality and health benefits of probiotic supplements may vary widely.
The second experiment of Objective 1 measured β-gal activity of the supplements. This
enzyme activity is important in the breakdown of lactose, the main sugar in milk. Milk contains
4.8% lactose (Chandan, 1997). Many humans suffer from lactose intolerance, the inability to
digest lactose into its constituents, glucose and galactose, due to low levels of lactase enzyme in
the brush border of the duodenum (Rusynyk & Still, 2001). When undigested lactose remains in
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the gut of a lactose intolerant individual a range of symptoms can arise. These symptoms
typically occur within two hours of lactose ingestion and include abdominal pain, bloating,
borborygmi (stomach growling), diarrhea, nausea, and vomiting (van Griethuysen-Dilber,
Flaschel, & Renken, 1988). β–gal catalyzes the hydrolysis of lactose by breaking the β 1–4
linkage between glucose and galactose. Lactose is believed to trigger β- galactosidase activity
by the lac operon mechanism (Reznikoff & Miller, 1980).
Our results were consistent with previous studies in which the presence of lactose in
media enhanced β-gal activity when compared to the presence of glucose. Akolkar et al. (2005)
and Hsu et al. (2005) found that the presence of lactose in the media led to β-gal activity
enhancement for bifidobacteria and L. acidophilus specifically, which also supports the results
found in our study. We also examined the effect of bile on β–gal activity and found an increase
in enzyme activity when bile was included in the medium. This finding is consistent with that of
Zarate et al. 2000 who contributed this enzyme activity enhancement to the permeabilization of
probiotic strains by bile. This allowed more substrate to enter the cells to be hydrolyzed by β–
galactosidase (Zárate et al., 2000).
Overall lactose intolerant individuals can be well treated by dietary modification and
education one properly diagnosed with the condition (S. A. Ibrahim & Gyawali, 2013). Milk and
other dairy products can remain in the diet of lactose maldigesters without them experiencing
symptoms through this dietary modification. The addition of probiotics like supplement 5 could
be an effective means of alleviating lactose intolerance.
Objective 2 was conducted using supplement 5 which demonstrated a high viability and
maintained viability during refrigerated storage during Objective 1. In this objective we
attempted to understand the impact of aspirin and caffeine on the functionality of a probiotic
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supplement; functionality was determined by performing: (a) β- galactosidase activity, (b) bile
resistance, (c) reducing power, and (d) protein expression. The first experiment of the second
objective determined the impact of aspirin and caffeine exposure on the supplement. We used
both caffeine and aspirin due to caffeine‘s use as an adjuvant to the analgesic actions of aspirin
and paracetamol, and because of the high consumption of caffeine containing products such as
coffee and tea (Gokulakrishnan et al. 2004). Caffeine is a purine alkaloid which acts as a central
nervous system stimulant and also has negative withdrawal effects (Gokulakrishnan et al. 2004).
Coffee and tea plants are the major sources of natural caffeine. Average consumption of caffeine
in humans ranges from 80-400 mg/ (person day) (Gokulakrishnan et al. 2004).
Exposure to aspirin was found to decrease bacterial population approximately 6.75 log
CFU/ml, and exposure to caffeine decreased population approximately 0.23 log CFU/ml. Our
results are supported by research that has also demonstrated the negative impact of aspirin on
survival rate of probiotic bacteria. Thus indicating the possible negative role of aspirin, in certain
doses, on the microbiota.
The second experiment of Objective 2 determined the effect of aspirin and caffeine on the
β-gal activity of supplement 5. Aspirin exposure caused a decrease in enzyme activity while
caffeine caused a significant increase. This increase in enzyme activity is believed to be
contributed to caffeine hydrolyzing the cell membrane, allowing for the nutritive media to enter
the cell.
The third experiment of Objective 2 investigated the survival of supplement 5 in the
presence of bile (3% w/v) and bile resistance. Supplement 5 demonstrated the ability to survive
in the presence of bile by exhibiting a slight decrease to 8.99 ± 0.04 from 9.14 ± 0.09 the control.
The survival of supplement 5 meets the criteria for probiotic bacteria.
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The fourth experiment of Objective 2 examined the reducing power of supplement 5.
Reducing power is often used to evaluate the ability of an antioxidant to donate an electron.
Although the reducing power of supplement 5 was found to be relatively low, the supplement
does prove to have some antioxidant properties.
The fifth experiment of Objective 2 determined the protein expression of supplement 5.
We found BPER useful for lysing bacteria, specifically probiotic bacteria. Our BCA results
showed that treatment, with caffeine and aspirin, reduced the total protein concentration of
bacteria. SDS Page using silver stain detected major protein bands. Treatment changed the
number and intensity of low molecular bands. There were unique target proteins affected by
caffeine and aspirin respectively. Overall, treatment with caffeine and aspirin both affected
concentration of the target protein.
In conclusion, during the protein expression experiment we identified a useful approach
using BPER and SDS Page (12% gel and silver stain) to evaluate probiotic quality that can
impact efficacy. Upon completion of the SDS page researchers concluded that the use of 12%
gels successful, and in terms of staining the gel a Silver stain was a better approach than the
Coomassie stain due to its sensitivity for detection of bacterial proteins. The results of both
the Silver and Coomassie stains can be found above (figures 13 and 14 respectively). Both stains
were allowed to set overnight.
Overall, the BCA (total protein), cell counts, and protein profile corroborate each other.
The protein profile indicates distinct proteins may be the target of aspirin and caffeine. The
prominent bands ~75-37 kD are not as susceptible as the lower weight band. Future studies could
investigate and identify these proteins and find what factors make them resistant to the effects of
aspirin and caffeine. In addition to affecting the viability of bacteria, treatment also affects the
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concentration and type of protein in probiotic bacteria. Further studies on the significance of
these proteins in probiotic health promoting functions are needed.
Table 5.1 provides a list of additional ingredients found in the probiotic supplements
investigated during this study. Many of these ingredients possess prebiotic properties that are
believed to boost the health promoting attributes of the probiotic cultures in the supplements. A
predominant ingredient in the dietary supplements is inulin (chicory root extract). This soluble
dietary fiber is not digested or absorbed in the stomach. Inulin passes through to the large
intestine where it ferments and is used by the microbiota as a fuel source. Ingredient content
could have an effect on the β- gal activity in the supplements.
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Table 11
β-gal activity of probiotic supplements (Miller units) and additional ingredients (excluding
probiotic strains).

Supplements

Induced

Uninduced

Ingredients

Supplement 1

15

0

Inulin (chicory root extract)
Hypromellose
Vegetable magnesium stearate
Silica
Titanium dioxide (color)

Supplement 2

775

0

Vitamin C
Cellulose powder
Dehydrated potato powder
Organic garbanzo bean (chick-pea) extract
Vegetable capsule (hypromellose)
L-leucine.

Supplement 3

885

860

Vegetable cellulose capsule
Cellulose
Stearic acid
Magnesium stearate
Maltodextrin

Supplement 4

715

700

Inulin (derived from chicory root)
Vegetarian capsule (hydroxypropylmethl-cellulose,
water)
InTactic proprietary polysaccharide complex
L-leucine

Supplement 5

1,120

50

Vitamin C (ascorbic acid)
NutraFlorascFOS (short-chain
fructooligosaccharides)
Plant-derived capsule
Aqueous enteric-coating (modified cellulose, sodium
alginate, stearic acid, fractionate [non-hydrogenated]
coconut oil, Oleic acid)

Supplement 6

1,070

28

Supplement 7

160

12

FOS (fructooligosaccharides)
Kosher vegetable capsules
Vegetable cellulose
Vegetable magnesium stearate

Supplement 8

1,065

26

Microcrystalline cellulose
Vegetable cellulose

Magnesium stearate
Rice starch
Vegetarian capsule (cellulose, water)
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Tapioca starch
Ascorbylpalmitate
Silica
Supplement 9

6

5

Gelatin
Starch (potato, tapioca and corn)
Silica

Supplement 10

1.45

0

Calcium carbonate
Sodium croscarmellose
Silica
Magnesium stearate (vegetable source)
Rice maltodextrin
Vegetable coating
Bacterial proteases

Based on the results of this study we found that storage of probiotic supplements effects
viability and believe that there is a need to address increasing the knowledge on the effects of
storage on probiotic products to ensure health benefits are conferred to consumers. We also
found that aspirin can reduce the bacterial population of probiotic supplements. However recent
studies have found that the dosage of 81 mg of aspirin may not decrease the microbiota
population, but change it. Future work should be directed toward the dosage of aspirin and the
functionality of the microbiota in order to understand how these two components may work
together in promoting heart health. The change in the functionality of the microflora could be a
key element in how the microbiota and aspirin work together in heart attack prevention.
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